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1  Summary 
 
Dilated cardiomyopathy is a leading cause of heart failure in young patients in 
developed countries and often evolves from myocarditis. The mouse model of 
experimental autoimmune myocarditis (EAM) mirrors many aspects of the 
physiopathology of human myocarditis. In mice, the time course of 
myocarditis is biphasic, reflecting an early acute chronic myocarditis followed 
by a low-grade of inflammation with heart muscle fibrosis and ventricular 
dilation. Using the EAM model, I elucidated the role of CD4+ T helper (Th) 
cells in inflammatory heart disease. My aim was, on one side, to understand 
the mechanism that leads to the spontaneous resolution of inflammation after 
the acute phase of cardiac inflammation, and, on the other side, to find a 
vaccination strategy to shift the polarization of CD4+ Th cells to a biased 
protective heart-specific cell response.  
To answer the first question, I used mice lacking the receptor for IFN-! (IFN-
!R-/-), because they were extremely susceptible to autoimmune myocarditis. 
After EAM induction, the number of inflammatory heart-infiltrating cells in IFN-
!R-/- mice was considerably higher compared to wild-type (wt) mice, 
suggesting that a deeper study of the heart-infiltrating cells was necessary. 
The origin of those cells was elucidated creating CD45.2 chimeric mice 
reconstructed with CD45.1 bone marrow. Myocarditis induced in chimeric 
mice showed that all heart-infiltrating cells were from the bone marrow of 
donor mice. After providing evidence that Th17 CD4+ T cells mediated EAM, 
the question of a direct involvement of the Th17 cytokine IL-17 arose. In fact, 
as expected, systemic depletion of IL-17 with blocking antibodies confirmed a 
direct role of IL-17 in the recruitment of inflammatory cells into the heart. A 
deeper analysis of the recruited cells showed that CD11b+ monocytes were 
the major heart-infiltrating cell population. A comparison of the anti-
inflammatory potential of wt and IFN-!R-/- CD11b+ monocytes revealed that 
IFN-!R-/- CD11b+ monocytes were not able to inhibit heart-specific CD4+ T 
cells. The relevance of the IFN-!R signaling pathway for the transcription of 
anti-inflammatory molecules, like inducible nitric oxide synthase (NOS2), was 
tested in vitro. Indeed, IFN-!R-/- monocytes showed an impaired capacity to 
4 
 
produce the short living molecule nitric oxide, which is able to reversibly inhibit 
T cell proliferation. In vivo, serial injections of wt CD11b+ monocytes into 
diseased IFN-!R-/- mice were sufficient to provide a good number of functional 
CD11b+ monocytes to block EAM in high susceptible IFN-!R-/- mice. 
Dendritic cells subsets differently regulate autoimmunity. In fact, bone 
marrow-derived dendritic cells (bmDC) promoted IL-17-mediated EAM, while 
splenic CD"+ dendritic cells were slightly pathogenic and induced low levels 
of EAM. CD8"+ DC stimulated with LPS-"CD40, producing high levels of IL-
1# and IL-6, induced the development of auto-aggressive IL-17-producing 
CD4+ Th17 cells, while TNF-"-stimulated CD8"+ DC polarized IFN-!-
producing CD4+ Th1 cells. The potential of CD8"+ DC to induce protective 
IFN-!-producing T cells was used to develop a vaccination strategy. Indeed, 
mice vaccinated with serial injections of self-peptide-loaded and TNF-"-
stimulated CD8"+ DC showed an increased production of IFN-! by self-
peptide-specific CD4+ T cells and were protected from EAM. 
Taken together, the opposite roles of IFN-! as protective cytokine and IL-17 

















2  Aim of the thesis 
 
EAM represents a CD4+ T cell-mediated autoimmune heart disease.  
Autoimmune diseases develop in susceptible animals when a threshold of 
self-tolerance exceeds. Many autoimmune diseases are linked with preceding 
microorganism infections that cause damage of tissues, cross-reaction with 
self-antigens, and activation of the immune system. The activation of the 
innate immune system through toll-like receptors (TLR) stimulation in concert 
with the activation of the adoptive immune system is strictly necessary to 
develop heart failure. Activated dendritic cells (DC) strongly prime naïve T 
cells, which quickly become heart-specific auto-aggressive T cells. 
Historically, two major CD4+ T cell subsets have been defined according to 
their cytokine production pattern: IFN-!-producing Th1 cells, and Th2 cells 
secreting IL-4. Pathogenicity was mostly attributed to IFN-!. Recent data, 
however, demonstrate that mice with an impaired IFN-! signaling pathway are 
highly susceptible for EAM development and have a high mortality rate. 
Moreover, a novel autoreactive CD4+ T cell subpopulation characterized by 
IL-17 production is present at increased levels in IFN-!-/- mice with ongoing 
EAM. A deeper understanding of IL-17 and its inflammatory function in EAM 
was the first aim of my thesis. Afterward, I focused on the role of IFN-! in 
EAM. High susceptible IFN-!R-/- mice and wt mice showed comparable levels 
of inflammatory heart-infiltrating cells and IL-17 production at the peak of 
EAM. Afterwards, however, wt mice drastically reduced the number of heart-
infiltrating cells and levels of IL-17, while IFN-!R-/- mice still presented very 
high quantities of inflammatory heart-infiltrating cells and IL-17 production. I 
aimed to find the protective function of IFN-! in CD4+ Th17 cell-mediated 
EAM.  
DC are powerful regulators of the immune system. In the last years, most of 
the cells used to elucidate and explain autoimmune diseases were DC from 
bone marrow origin cultivated with GM-CSF. In EAM, it is known that self-
peptide-loaded and LPS/"CD40-stimulated bmDC modulate a strong CD4+ 
Th17 response, which leads to EAM in susceptible mice. However, in contrast 
to bmDC, other DC subpopulations were more prone to polarize CD4+ Th1 or 
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CD4+ Th2 cells rather than CD4+ Th17 cells. Some dendritic cells from the 
spleen, for example, ex vivo cultivated with naïve T cells, preferentially induce 
CD4+ T cells to produce IFN-!. I took advantage from these splenic DC and I 
focused my work on the development of a vaccination strategy to protect mice 
and prevent EAM.  
Taken together, I aimed my thesis to clarify the opposing roles of IFN-! and 




3  Introduction  
 
3.1  Innate and adaptive immunity 
The main role of the immune system is to protect the body from infection. The 
system is divided into two major branches: the innate immune system and the 
adaptive immune system. The innate immune system is non-specific, as it 
fights any type of invading pathogen, and is ready to be mobilized upon the 
first signs of infection. The adaptive immune system specifically attacks the 
invading pathogens and requires some time to develop its custom-made 
response. The adaptive system produces memory cells that are able to 
remember antigens it has encountered and reacts more quickly and efficiently 
the next time that antigen is found, yet more slowly than the innate system. 
Over the past years, research into the causes of autoimmune diseases has 
largely focused on the adaptive immune system because of its remarkable 
ability to generate specific immunity to antigens. Recently, however, many 
scientists are considering the innate immune system as a major player in 
autoimmune disease. The innate system, though less specific than the 
adaptive system, is less able to discriminate low from high pathogenic 
antigens and to generate a potent primary defense against infections. It is 
becoming clear that autoimmune diseases frequently involve the innate as 
well as the adaptive immune system. 
Activation of the innate immune system is mediated by pattern recognition 
receptors (PPR) on APC that recognize pathogen-associated molecular 
patterns (PAMPs) like polysaccharide and polynucleotide (1). The best-
characterized signaling PPR are so far the Toll-like receptors (TLRs), which 
are very able to differentiate between molecular patterns found on pathogens 
and molecular patterns found on the body’s own cells. Indeed, TLR responses 
are limited and specifically aimed against foreign pathogens and not against 
self-tissues (2). Whereas TLRs that recognize bacterial and fungal cell wall 
components are localized to the cell surface, TLRs that recognize viral or 
microbial nucleic acids are localized to intracellular membranes and are 
thought to encounter their ligands in phagosomes or endosomes. This 
localization is thought to be an adaptation ensuring that these receptors 
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detect nucleic acids released from apoptotic host cells, microbial cells or 
virions only after phagocytosis and partial digestion of the ingested particles 
has released the nucleic acids.  
The innate response can be enhanced immediately without any delay, but as 
a consequence there is no memory evolving after an encounter with a specific 
pathogen. This response will be determined by the binding to one or more of 
the twelve in mammals known different TLRs. In this way, the TLRs identify 
the nature of the pathogen and turn on an effector response appropriate for 
dealing with it. These signaling cascades lead to the expression of genes 
encoding various cytokines.  
  
The adaptive immune response is the most advanced and specialized arm of 
immunity and is found in vertebrates only. The components of the adaptive 
immune system are two major types of immune cells, T and B cells (also 
called lymphocytes). They display a large variety of cell surface receptors that 
can recognize and respond to an unlimited number of pathogens. To do that, 
the adoptive immune system needs to generate large numbers of receptors. 
To reach a high level of variability, recombination of pre-existing gene 
segments is necessary to encode B- and T-cell receptor (BCR and TCR, 
respectively) genes. Variations are created in the antigen-recognition regions 
of BCR and TCR. The mechanism involves a series of recombination events 
that fuse variable (V), diversity (D), and joining (J) gene segments in a 
process called V(D)J recombination. This is achieved by a well-coordinate set 
of reactions, starting with two lymphocytes-specific proteins called RAG1 and 
RAG2 that recognize and bind specific conserved recombinant signal 
sequences (RSSs). This complex cuts the DNA between the rearranging DNA 
segments and the adjacent RSS motifs. Pre-existing V, D, and J gene 
segments are rearranged to yield a contiguous V(D)J region, just upstream of 
another element of the receptor, the constant (C) region. This process is 
ensured by ubiquitous DNA repair enzymes, which control the functionality of 
the double-stranded DNA and correctly complete the joining process.  
The antigen-recognition regions of BCR and TCR consist of two paired protein 
segments, the heavy (H) and light (L) chains, and the " and # chains, 
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respectively. The BCR heavy chain and the TCR # chain consist of V, D, and 
J segments, while the BCR light and the TCR " chain consist only of V and J 
segments. As both BCR and TCR are heterodimers, a huge amount of 
possible rearrangements allow the recognition of an unlimited number of 
antigens. 
Although the adoptive immune system can recognize a lot of different 
antigens, it responds slower (3-5 days) than the innate immune response, 
because only a small fraction of cells will have a receptor for a certain antigen 
and those cells will need to undergo clonal expansion. This specific antigen 
response comes with one major benefit, as an immunological memory is build 
up and maintained after an encounter with a specific pathogen, with a fast 
memory response upon a second challenge with the same antigen or 
pathogen. 
 
3.2  Self-tolerance 
The immune system uses several mechanisms to control and avoid reactions 
against own organs, tissues and proteins. One hallmark of the vertebrate 
immune system is self-tolerance, which works to protect tissue antigens from 
becoming targets of damaging immune responses during clearance of 
infections. The immune system normally exhibits specificity in distinguishing 
infectious antigens from self-antigens. The immune response is regulated by 
opposing immunogenic and tolerogenic signals, and the latter normally prevail 
for lymphocytes that bind self-antigens. Self-tolerance is induced in the 
thymus by thymic negative selection of autoreactive T cells and in the 
periphery by mechanisms inducing cell death and cell anergy, and by 
suppressor regulatory-T cells. Abrogation of these processes, as well as 
disturbance in the balance between immunogenic and tolerogenic signals, 
can lead to autoimmunity.  
T-cell development is a highly coordinated process that depends on 
interactions between thymocytes, thymic epithelium, and bmDC (3). Before 
entering the peripheral T-cell pool, thymocytes are subject to negative 
selection, a process that eliminates T cells with high affinity to self-antigens. 
Thymocytes, which are of bone marrow origin, undergo several maturation 
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and developmental stages prior to becoming mature T cells.  
The thymus is arranged into an outer cortex, which contains immature 
thymocytes, and an inner medulla, which contains mature thymocytes. 
Double-negative immature CD4-CD8- thymocytes undergo a proliferative 
expansion that give rise to the main population of double-positive CD4+CD8+ 
thymocytes. V(D)J rearrangement of TCR is achieved during this maturation 
stage. Afterwards, double-positive thymocytes undergo one of three cell fates: 
death by neglect, positive selection or negative selection. Death by neglect is 
a passive form of cell death caused by the failure of TCR to engage a peptide-
MHC ligand. About 90% of double-positive thymocytes fail to undergo positive 
selection and die because they do not receive a survival signal. Positive 
selection occurs when TCR encounters a peptide-MHC ligand with low 
affinity, resulting in the transduction of a survival and transduction signal.  In 
this process, single-positive cells expressing CD4 but not CD8 develop and 
recognize foreign peptides in association with class II MHC proteins, while 
cells expressing CD8 but not CD4 develop and recognize foreign peptides in 
association with class I MHC proteins. Negative selection occurs when the 
TCR contacts with a peptide-MHC ligand with high affinity, causing 
thymocytes to die rapidly via apoptosis. This process destroys T cells with 
potential autoreactivity, providing a repertoire of peripheral T cells that is 
largely self-tolerant. Double positive CD4+CD8+ thymocytes undergoing 
negative selection react to both ubiquitous expressed antigen and tissue-
specific antigens (TSAs).  It is not completely clear whether negative selection 
occurs in the thymic cortex or medulla. However, expression of TSAs in the 
thymus is mostly a property of medullary thymic epithelial cells (mTECs) (3). 
In fact, mTECs are sites of promiscuous gene expression and transcribe 
genes that are normally expressed in peripheral tissues. In this way, 
medullary epithelial cells might be able to express the entire peptide repertoire 
of the individual, making the medulla an ideal site for negative selection. The 
number of mTECs that express any given self-peptide might be relatively 
small, implying that a thymocyte must scan several of these epithelial APCs to 
view the entire self-peptide repertoire. An important aspect of the medullary 
epithelium is the expression of a transcription factor known as autoimmune 
regulator (AIRE). AIRE is highly expressed in mouse and human mTECs, and 
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mutations in the AIRE gene are responsible for the rare human autoimmune 
syndrome called autoimmune polyendocrinopathy-candidiasis-ectodermal 
dystrophy (4). AIRE-deficient mice also develop multi-organ autoimmune 
disease. mTECs in AIRE-deficient mice also lack expression of a subset of 
TSAs linking thymic TSAs expression with T-cell tolerance (5, 6). mTECs 
expressing high levels of MHCII and CD80 are the subsets of mTECs that 
express AIRE and the highest number of TSAs (6). 
Although negative selection is a very precise mechanism, it is not absolutely 
perfect. In fact, several auto-aggressive T cells pass the negative selection 
and are exported.  Self-reactive T cells that escape negative selection in the 
thymus must be inactivated in the periphery. Anergy constitutes one means of 
imposing peripheral tolerance. Clonal anergy refers to a state of 
unresponsiveness that is induced in potentially dangerous lymphocytes during 
antigen recognition. Different mechanisms of anergy include block in TCR 
signaling, the activation of ubiquitin ligases, and the engagement of inhibitory 
receptors (7) (8). Co-stimulatory signals between T cells and APC play an 
important role in T-cell anergy. Both CD28 and CTLA-4 receptors on T cells 
bind the ligands B7-1 (CD80) and B7-2 (CD86) on antigen-presenting cells 
but exert opposite influences on T-cell activation. CD28 stimulation promotes 
T-cell activation, whereas CTLA-4 stimulation inhibits T cells. CTLA-4 is a 
counter-regulatory molecule known to antagonize CD28 both by binding CD80 
and CD86 and by inhibiting cell cycle progression. Although the simple 
absence of co-stimulation is sufficient to induce anergy in effector T cells, 
CTLA-4 engagement may be necessary to induce anergy in naïve CD4+ T 
cells. In fact, cells lacking CTLA-4 have a reduced potential in tolerization of T 
cells.  
Not only molecular components of T-cell signalling are involved in T-cell 
anergy. Also E3 ubiquitin ligases, important enzymes of the ubiquitin–
proteasome system, are an essential component of the T-cell anergy 
phenotype. Among E3 ubiquitin ligases, there are three which mediate the 
selective degradation of specific signaling protein: Itch and Cbl-b, whose 
mutation or deletion in mice is associated with disseminated autoimmune 
disease, and GRAIL, a transmembrane, endosome-associated protein 
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whose overexpression blocks IL-2 induction (9). Several different proteins 
are involved in peripheral T-cell anergy, but many of them are still under 
investigation.  
All together, a failure in one of those auto-regulatory mechanisms may lead 
to unwanted expansion of self-reactive T cells, to the production of self 
antibodies, and eventually to autoimmune diseases. 
 
3.3  Autoimmune diseases 
Autoimmune diseases represent the third most common category of disease 
in the United States after cancer and heart disease. They affect approximately 
5-8% of the population (about 14–22 million persons). About 80% of them are 
women (10). Autoimmune diseases can affect virtually every site in the body, 
including the endocrine system, connective tissue, gastrointestinal tract, heart, 
skin, and kidneys. At least 15 diseases are known to be the direct result of an 
autoimmune response, while circumstantial evidence implicates >80 
conditions with autoimmunity (11). Autoimmune diseases are divided in two 
classes by their auto-antigen targets: organ specific and systemic diseases. 
Organ specific diseases include type I diabetes mellitus, multiple sclerosis, 
myasthenia gravis, autoimmune thyroiditis diseases, and autoimmune 
myocarditis, while systemic diseases include systemic lupus erythematosus, 
rheumatoid arthritis, antiphospholipid syndrome, and scleroderma (12).  
Autoimmune disease occurs when T cells that escaped auto-regulatory 
mechanisms develop a response against self-antigens. Besides T cells, B 
cells or autoantibodies can induce injury systemically or against a particular 
organ. Understanding of autoimmune diseases is obstructed by the fact that 
some level of autoimmunity, in the form of naturally occurring autoantibodies 
and self-reactive T and B cells, is present in all normal persons (13). Thus, on 
a proportional basis, developing autoimmune disease is the relatively 
uncommon consequence of a common autoimmune response. Although an 
autoimmune response occurs in most persons, clinically relevant autoimmune 
disease develops only in susceptible persons. A body of circumstantial 
evidence links many autoimmune diseases with preceding bacterial infections 
(14, 15). Since infections generally occur before the onset of symptoms of 
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autoimmune disease, linking a specific microorganism to a particular 
autoimmune disease is difficult. One possible explanation is the presence of 
sequence homologies between the pathogen and self-proteins, which results 
in cross-reaction with self-antigens, and then induction of autoimmunity (16, 
17). This mechanism is called “molecular mimicry”. Molecular mimicry, 
however, has been demonstrated in animal models, but not in human 
diseases (18-20). Another explanation is that microorganisms expose self-
antigens to the immune system by directly damaging tissues during an active 
infection. This mechanism has been referred to as the "bystander effect" (21). 
However, whether pathogens mimic self-antigens, release sequestered self-
antigens, or both, is difficult to determine.  
Other non-specific mechanisms are involved in induction of autoimmunity 
after infection. In general, a secondary signaling is necessary to trigger 
autoimmune diseases. The so-called “adjuvant effect” leads the innate 
immune system to produce restricted responses to particular classes of 
pathogens through PRR, such as TLR (22, 23). Interaction of the 
microorganism component of adjuvants with PRR results in activation APCs 
and up-regulation of molecules essential for antigen presentation and 
production of pro-inflammatory cytokines. However, usually, adjuvant alone 
(that means without self-antigens) does not result in autoimmune disease. 
In a broader view, microorganisms have to be considered to provide both the 
adjuvant effect to stimulate the immune response and the damage necessary 
to make self-antigens available to the immune system, resulting in 
autoimmune disease.  
 
3.4  Autoimmunity in inflammatory heart diseases 
Dilated cardiomyopathy represents the most common cause of heart failure in 
young patients and often evolves from myocarditis (24-26). Myocarditis is 
defined by the Dallas criteria as "the presence of an inflammatory infiltrate in 
the myocardium with necrosis and/or degeneration of adjacent myocytes" (27, 
28). Worldwide, infections with the parasitic protozoan Trypanosoma Cruzi 
(Chagas disease), which is endemic in Southern America, are the leading 
cause of myocarditis. In developed countries, however, viral infections are 
common triggers of cardiac inflammation (24-26, 29). Besides enteroviruses 
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or adenoviruses, Parvo-, Hepatitis C-, Human Immunodeficiency- HHV-6, 
HHV7, Cytomegalo-, Epstein-Barr viruses have been detected in hearts of 
patients with inflammatory dilated cardiomyopathy (25, 26). Virus infections 
directly contribute to cardiac tissue destruction by cleaving the cytoskeletal 
protein dystrophin, leading to a disruption of the dystrophin-glycoprotein 
complex (30). Moreover, clinical observations and insights from animal 
models provide evidence that autoimmunity plays a relevant pathogenetic role 
in most cases of human myocarditis and in many patients with dilated 
cardiomyopathy (31). Notably, many patients with dilated cardiomyopathy 
develop heart-specific autoantibody responses (30). Myocytes isolated from 
patients with diagnosed myocarditis and idiopathic DCM often display 
increased levels of MHC class I and class II proteins (32), and myocarditis 
commonly develops in patients with systemic autoimmune disease (25). In 
addition, immunosuppressive therapy can improve heart function in 
subgroups of patients, particularly in individuals without evidence for 
persistence of viral genomes in heart biopsies (33, 34). Such findings have 
given rise to the hypothesis that while pathogenic attack may be responsible 
for an acute phase of myocarditis, post-infectious autoimmunity is responsible 
for chronic inflammation of the myocardium (24). 
 
3.5  The experimental autoimmune myocarditis (EAM) model 
In several susceptible mouse strains, infections with the human pathogenic 
Coxsackie type B3 (CVB3) virus result in chronic myocarditis progressing to 
heart failure, even after clearance of the virus (35, 36). In mice, chronic 
myocarditis following CVB3 infection is T cell mediated because adoptive 
transfer of T cells, but not serum from diseased mice transfers disease in 
SCID recipients genetically lacking B and T cells (37). Furthermore, peripheral 
blood lymphocytes from patients with dilated cardiomyopathy transfers 
disease to SCID mice (38, 39). Inflammatory infiltrates in affected mouse 
hearts are characterized by the interstitial and patchy accumulation of 
mononuclear cells and mirror the histologic pattern observed in human 
myocarditis. The marked reduction of inflammation in infected mice after 
depletion of CD4+ T cells, and the partial reduction of disease severity after 
depletion of CD8+ T cells, suggest that T cells play an important role in the 
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progression of myocarditis in CVB3 infected mice (37, 40, 41). Taken 
together, these findings indicate that heart-specific autoimmunity plays an 
important role in post-viral myocarditis and argue for a critical role of T helper 
cells in disease development. 
Immunization models offer the advantage to study the disease pathogenesis 
in vivo in the absence of infection. Indeed, immunization with alpha-myosin or 
specific alpha-myosin peptides together with strong immunostimulants, such 
as CFA, induces heart-specific inflammation (EAM) in susceptible mouse 
strains, such as BALB/c (H-2d) and A/J (H-2a) mice (42, 43). The most 
pathogenic epitope for BALB/c mice has been identified on the alpha-myosin 
heavy chain protein (43). Activation of APC, taking up and processing self-
antigen, is a prerequisite for T-cell priming. TLRs represent a family of 
transmembrane receptors that are essential for innate immune responses to 
pathogens. The different TLRs exhibit different specificities for microbial 
patterns such as LPS, or double-stranded RNA, as well as for some 
endogenous products such as stimulatory signals released by dying cells. 
Recently, it was shown that alpha-myosin-loaded dendritic cells activated 
through TLR ligands such as LPS or double stranded RNA can induce 
autoimmune myocarditis in BALB/c mice (44). Disease induction by 
vaccination with self-antigen-loaded dendritic cells offers an attractive 
approach to study the APC-effector-cell interactions and priming mechanisms 
of autoimmune T cells in vivo. 
EAM can be induced in susceptible mouse strains by immunization with self-
peptides derived from the MyHC-" together with a strong adjuvant like CFA 
(42), or by injection of activated, MyHC-"-loaded dendritic cells (44-46). In 
BALB/c mice, myocarditis severity peaks 21 days after the first myosin-
peptide/CFA immunization or 10-14 days after the first injection of activated, 
peptide-loaded dendritic cells. Later on, most inflammatory infiltrates resolve 
spontaneously, but some animals develop fibrosis and dialed cardiomyopathy. 
In affected mice, impaired cardiac contractility correlates with the percentage 
of CD4+ T cells among heart-infiltrating CD45+ cells at the peak of disease. In 
fact, depletion of CD4+ T cells in A/J (H-2a) mice led to protection from 
myocarditis after subsequent myosin immunization, whereas depletion of 
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CD8+ T cells reduced severity but not prevalence of disease (37, 40). The 
decisive role of CD4+ T cells in autoimmune myocarditis induction, however, 
was shown in adoptive transfer experiments. Injection of in vitro restimulated 
CD4+ T cells isolated from MyHC-"-immunized diseased mice induced 
myocarditis, albeit at a low severity grade, in severe combined 
immunodeficient (SCID) mice or LPS pretreated wild-type mice (37). 
Importantly, however, adoptive transfer experiments do not work in naïve wild-
type mice. 
 
3.6  T helper cells: the changing hypothesis about Th1, Th2, Th17 cells 
EAM represents a CD4+ T cell-mediated disease. Historically, two major CD4+ 
T cell subsets have been defined according to their cytokine production 
pattern: IFN-!-producing Th1 cells, and Th2 cells releasing IL-4. The majority 
of the heart-infiltrating cells share a monocyte/macrophage phenotype, 
suggesting that Th1 signals predominate. In addition, signaling through the 
receptor of the key Th2 cytokine IL-4 is dispensable for EAM development 
(47, 48). These findings would point to a pathogenic role of Th1 differentiation 
in EAM. However, loss of either the Th1 effector cytokine IFN-! or its receptor 
results in markedly increased disease severity, implying that the key Th1 
cytokine IFN-! is a negative regulator of EAM (47-50). In addition, mice 
lacking T-bet, a T-box transcription factor essential for Th1 lineage 
differentiation, show enhanced myocarditis severity (47).  
These apparently contradictory findings were finally explained by analysis of 
gene-targeted mice with mutations in the Th1-driving cytokine IL-12 and its 
receptor. IL-12p70 binding to the IL-12 receptor represents a heterodimer 
consisting of an IL-12p40 and an IL-12p35 subunit. The IL-12p70 receptor, on 
the other hand, consists of an IL-12R#1- and an IL-12R#2-subunit, and 
induces the recruitment of JAK2 and activation of STAT4 upon activation. 
Experiments with knock out mice revealed that both, the IL-12#1 and the IL-
12p40 subunit, were essential for myocarditis induction (47, 48, 50). In 
contrast, IL-12p35-deficient mice developed more severe autoimmune 
myocarditis compared to wild-type littermate controls (47). These apparent 
paradoxical findings were finally explained by the discovery that IL-12p40 
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represents a shared subunit between IL-12p70 and IL-23, another cytokine of 
the IL-12 family. IL-23 is composed of IL-12p40 and a distinct p19 subunit. 
Moreover, the IL-23 receptor shares the #1 chain with the IL-12p70 receptor. 
IL-23 has recently been recognized as a key mediator promoting the 
expansion and survival of another subset of CD4+ T cells characterized by the 
production of the cytokine IL-17. Several lines of evidence clearly suggest that 
IL-17-producing CD4+ Th17 cells represent a distinct subset of CD4+ T cells,  
Fig 1.1. Effector differentiation of CD4+ T-cell subsets. Following activation, naïve CD4+ T 
cells differentiate towards Th1 in the presence of IL-12, which upregulates IFN-! via Stat4, 
leading to IFN-!-mediated Stat1 activation and induction of the Th1 lineage determining 
transcription factor Tbet. Th2 by contrast differentiates in response to IL-4, which activates 
Stat6, resulting in induction of GATA3. The Th17 T-cell subset develops in response to IL-6 
and TGF-!, and this differentiation step is strongly inhibited by Th1 or Th2 cytokines. 
Signaling via IL-6 activates Stat3 and the lineage-determining transcription factor ROR!t. 
Signaling through TGF-! receptor is also essential for Th17 development, as T cells defective 
in TGF-!RII signaling cannot differentiate to Th17. (Stockinger B and Veldhoen M, Curr Opin 
Immunol, 2007, modified).  
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developing as a Th1 and Th2 cell independent lineage (51-54). Th17 cells 
play a key role in the development of various models of chronic and 
autoimmune inflammation, such as experimental autoimmune 
encephalomyelitis (54), graft-versus-host disease (55), and allergic asthma 
(56). Recent data provided evidence that autoimmune myocarditis 
development critically depends on the IL-23-STAT4 axis (50) and on the 
expansion of heart-specific Th17 CD4+ T cells (47, 57-59). Notably, the direct 
pathogenic role of Th17 cells was illustrated in adoptive transfer experiments. 
Immunization of mice with MyHC-"/CFA results in relatively low numbers of 
heart-specific Th17 cells in peripheral lymphatic organs. This observation 
explains why adoptive transfer with in vitro re-stimulated CD4+ T cells isolated 
from draining lymphnodes or spleens of diseased mice results in minimal 
cardiac inflammation only. Selective in vitro expansion of MyHC-"-specific IL-
17-producing CD4+ Th17 cells in the presence of recombinant IL-23 and anti-
IL-12p70 antibodies, however, yields heart-specific Th17 cell lines which are 
highly pathogenic after transfer in wild-type mice (59). Based on these 
findings, the question arises whether IL-17 is rather a surrogate marker of a 
pathogenic T helper cell subset or a disease promoting cytokine by itself. The 
observations that systematic depletion of IL-17 in MyHC-"/CFA-immunized 
mice by an anti-IL-17 antibody (59) or by active vaccination (57) both 
ameliorate disease severity and the recruitment of inflammatory cells, suggest 
a direct pathogenic role of IL-17 in EAM. 
 
3.7  Cytokines promoting Th17 lineage commitment  
Activation of antigen presenting dendritic cells trough Toll-like receptors 
results in up-regulation of MHC class II as well as co-stimulatory molecules. 
Activated dendritic cells produce high amounts of pro-inflammatory cytokines, 
which exert auto- and paracrine effects on both, antigen-presenting cells as 
well as T cells. Major pro-inflammatory cytokines released by TLR activated 
dendritic cells include IL-12p40, IL-1#, IL-6, and TNF-", which are all critical 
for EAM induction and progression (44, 46, 47, 60). Gene-targeted mice 
lacking the TNFRp55receptor, for example, are protected from disease, and it 
had been hypothesized that TNF-" mediates the activation of heart resident 
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dendritic cells as well as adhesion molecules on the vascular endothelium 
(61). 
Interaction of different cytokines is necessary for the development of the Th17 
lineage. Th17 differentiation is initiated by IL-6 and TGF-! (Fig. 1.1) (62, 63). 
Moreover, also IL-1 is considered necessary for Th17 initiation (64). In fact, 
mice lacking IL-1, IL-6, or TGF-#, present an impaired Th17 development and 
an increased production of Th1 and Th2 (64, 65). As mentioned before, IL-23 
is a critical mediator for the expansion and survival for the pathogenic Th17 
subset (51-53). Th17 cells produce IL-17, IL-17F, and IL-22, all of which 
regulate inflammatory responses (66, 67). IL-21 is considered as an autocrine 
factor induced by IL-6 to regulate Th17 differentiation (68, 69). Cytokines that 
usually trigger differentiation of Th1 and Th2 cells, as IFN-! and IL-4, 
negatively regulate Th17 differentiation (51, 53).  
Analogous to STAT4 and STAT1 in Th1 and STAT6 in Th2 differentiation, 
STAT3 mediates Th17 differentiation (70, 71). Overexpression of STAT3 
enhances Th17 differentiation, whereas STAT3 deficiency impairs Th17 
differentiation in vitro (70, 71) and in vivo (72). The precise biochemical 
function of STAT3 is not completely clear. Although STAT3 has been shown 
to bind to the IL-17 gene promoter (73), STAT3 appears to control more than 
just IL-17 gene expression (71). Similarly to STAT1 and STAT6, STAT3 
seems to be involved in regulation of lineage-specific master-transcription-
factor expression. One such Th17-specific transcription factor is a retinoid-
related orphan nuclear receptor, ROR!. The specific isoform ROR!t is the 
transcription factor to be selectively expressed in Th17 cells (74) and it is 
regulated by STAT3 (70, 71). Overexpression of ROR!t promotes Th17 
differentiation when Th1 and Th2 development is inhibited (74). On the 
contrary, lacking of ROR!t results in profound Th17 deficiency and protection 
from autoimmune diseases. However, ROR!t deficiency does not completely 
abolish Th17 differentiation, suggesting the involvement of other factors. 
Overexpression of another orphan nuclear receptor, ROR", which is induced 
by TGF-# and IL-6 in a STAT3-dependent manner (75), promotes Th17 
differentiation up-regulating IL-17. Lacking of ROR" results in reduced IL-17 
expression in vitro and in vivo, while double deficiencies in ROR" and ROR! 
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entirely impairs Th17 generation in vitro and completely inhibits autoimmune 
diseases (75). 
 
3.8  Interferon gamma (IFN-!) and nitric oxide (NO) 
IFN-!, a type II IFN, is considered a pro-inflammatory cytokine. In a broader 
view, IFN-! is one of the first cytokines involved in host defense when bacteria 
attack the body. Invading pathogens soon encounter macrophages, which 
activation is one of the first actions to occur in innate immunity. When 
activated, macrophages acquire microbicidal effector functions, secrete pro-
inflammatory cytokines, and respond to a range of different cell products and 
proteins during innate and adoptive immune responses. IFN-!, originally called 
macrophage-activating factor, is one of the most important cytokine that 
activates macrophages. The importance of IFN-! for macrophages is 
connected with the transcription of inducible nitric oxide synthase (NOS2), a 
crucial enzyme for the production of the short living radical gas nitric oxide 
(NO) (76, 77). NOS2 induction is regulated at transcriptional level by two 
discrete regulatory regions: region I contains LPS-related responsive 
elements, region II contains motifs for binding IFN-!-related transcription 
factors (78, 79). Single activation of one those regions only slightly increases 
NOS2 transcription, whereas simultaneous cooperation of both regions highly 
increases NOS2 expression (78, 79). NOS2 has a relevant function in host 
defense and in the cardiovascular system, whereas other nitric oxide 
synthases like endothelial nitric oxide synthase (eNOS) and neural nitric oxide 
synthase (nNOS) seem not to be involved in these two systems.  
Nitric oxide is considered one of the most potent mediators for T-cell inhibition 
and suppression. Activated NO-producing macrophages are extremely 
efficient T-cell suppressors (77). Especially inflammatory T cells are inhibited 
by macrophage-derived NO, which reversibly dephosphorylates intracellular 
signaling molecules involved in the control of T cell proliferation, like STAT5 
and Jak3 (24, 80). NO is an important regulator in autoimmune diseases. This 
is proven in mice lacking NOS2, which are high susceptible to develop auto-




3.9  Dendritic cells: key players in EAM regulation 
Dendritic cells are potent antigen presenting cells that induce primary T cell 
responses (83-86). Dendritic cells modulate peripheral tolerance, contributing 
to the expansion and differentiation of T cells that, in turn, regulate or 
suppress other T cells (87). These immunomodulatory functions are 
supported by several stimulatory signals, which determine the maturation 
stage of dendritic cells and the release of different levels of proinflammatory 
cytokines (87, 88). The efficient priming of heart-specific, autoreactive T cells 
requires co-operation between the innate and adaptive activation signals 
beyond an individual and genetically defined threshold level. Dendritic cells 
are sentinels of the immune system scavenging foreign pathogens as well as 
cell debris and necrotic tissues. Non-specific activation of dendritic cells 
through Toll-like receptors is supposed to be critical for autoreactive T cell 
priming. Once activated, CD40 ligand expressing autoreactive T cells further 
increase the priming efficacy of the dendritic cells by a positive feedback loop 
that promotes production of pro-inflammatory cytokines and survival of 
activated dendritic cells via CD40-CD40L interaction (45).  
Several lines of evidence point towards a critical role of dendritic cells in 
inflammatory heart diseases. Clinically total peripheral blood dendritic cells 
are elevated in patients with end stage heart failure (61). In mice, a specific 
subset of interstitial cells expressing the dendritic cell marker CD11c had 
been identified in perivascular heart tissue. Interestingly, these cells 
constitutively express cardiac self-antigens on MHC class II molecules even in 
the healthy heart (89). The number of these cells and up-regulation of their 
MHC class II expression parallels the development of cardiac inflammation 
(43, 90). The precise role of these heart resident dendritic cells is not clear.  
As mentioned above, dendritic cell activation is largely mediated by TLRs. 
Importantly, different TLR exhibit different specificities for microbial patterns 
such as LPS, or double stranded RNA, as well as for some endogenous 
products such as heat-shock proteins and other stimulatory signals released 
by dying cells (91). Accordingly, injection of mice with MyHC-"-loaded 
dendritic cells activated through TLR ligands such as LPS or CpG triggers 
autoimmune myocarditis and heart failure in susceptible BALB/c mice (45). 
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Furthermore, mice lacking the common adaptor molecule MyD88 for different 
Toll like receptors are protected from autoimmune myocarditis (60).  
Antigenic mimicry can put the organism at risk for autoimmune heart disease. 
An immune system that was exposed to symptomatic or sub clinical infections 
with any microorganisms containing self-antigen like structures could be more 
susceptible to boost an autoreactive T cell response after a second hit that 
releases self-antigen on the background of a non-specific inflammatory 
response (24). In fact, some patients develop heart-specific autoimmunity 
after non-infectious tissue damage, for example after cardiac surgery or 
myocardial infarction (92, 93). It is conceivable that tissue damage of any 
cause results in uptake of self-antigens by dendritic cells. If dendritic cells, 
which uptakes self-antigens, become activated, might initiate an autoimmune 
response depending on the genetic susceptibility of the affected individual 
(94, 95). It seems that activation of self-antigen-loaded dendritic cells boost 
autoreactive T cells, aggravating cardiac inflammation. 
Dendritic cells are not only essential for the induction of autoimmune T cell 
responses and diseases. Dendritic cells stimulated with the inflammatory 
cytokine TNF-" in the absence of a strong TLR stimulant become semi-
mature dendritic cells, while exposure TLR stimulants, especially in the 
presence of CD40 ligation, rather results in mature activated dendritic cells 
(96, 97). Interestingly, bone marrow-derived semi-mature, i.e. TNF-"-
stimulated dendritic cells (bmDC), expressing CD11c+ and CD11b+, but not 
CD8"+, confer antigen-specific protection from autoimmunity in the mouse 
models of experimental autoimmune encephalomyelitis (EAE) (98, 99), 
collagen-induced arthritis (100), and experimental autoimmune thyroiditis 
(EAT) (101). LPS plus "CD40 antibodies-stimulated bmDC, on the other 
hand, do not have any significant effect on the disease course (98-100). In 
contrast, as previously described, self-peptide-loaded bmDC stimulated with 
LPS plus "CD40 antibodies induce experimental autoimmune myocarditis 
(EAM) (44-46, 60) and experimental autoimmune uveitis (EAU) (102).  
Several lines of evidence indicate that other dendritic cells subsets have the 
potential to modulate various T cell responses. For example, in the spleen 
reside up to five subpopulations of dendritic cells with different capacity to 
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stimulate the proliferation of T cells (103). Indeed, some splenic dendritic cell 
subpopulations are able to modulate T cell differentiation promoting the 
production of anti-inflammatory cytokines (104-106). Splenic DC from 
lymphoid origin, which express CD8"+, can expand IFN-!-producing Th1 cells, 
while splenic DC from myeloid origin, lacking CD8" expression, promote IL-4-
producing Th2 cells (104-107). Phenotypically, CD8"+ DC express high levels 
of the typical DC-marker CD11c, but not CD11b, while CD8"- DC express 
high levels of CD11c, as well, but also the myeloid marker CD11b (106).  
As the amount of splenic DC expressing CD11c is less than 1% of all 
splenocytes (108), several cytokines are used to increase the number of 
these cells. One of the most used cytokine is FLT3L, a hematopoietic growth 
factor that stimulates the proliferation and differentiation of hematopoietic 
stem and progenitor cells (103). Mice treated with serial injections of FLT3L 
significantly accumulate DC in the spleen, lymph nodes, bone marrow, and 
liver (103, 109). Another important cytokine that expands DC is GM-CSF. 
Comparing the two cytokines, GM-CSF induces a biased myeloid lineage of 
dendritic cells which express high levels of CD11c and CD11b, but extremely 
low levels of CD8"+, whereas FLT3L induces DC of both lymphoid and 
myeloid origin (110). Recently, GM-CSF has been shown to be crucial for the 
development of pathogenic CD4+ Th17 cells in autoimmune myocarditis (65), 
suggesting that GM-CSF mostly acts as a pro-inflammatory cytokine, FLT3L, 




Figure 4.2. Intraperitoneal injection. 
(Experimental Critical Care Medicine Lab, 
Valaperti and Germano)  
Figure 4.1. Intravenous injection. 
(Experimental Critical Care Medicine Lab, 
Valaperti and Germano)  
4  Material and methods 
 
4.1  In vivo experiments 
 
4.1.1 MICE  
Mice were used at 6-8 weeks of age. Rag2-/-, IFN-!-/-, and DO11.10 mice (all 
BALB/c background) were obtained from The Jackson Laboratory. IFN-!R-/- 
mice have been backcrossed on BALB/c background by Prof. Urs Eriksson 
more than 10 times.  CD45.1 BALB/c mice were obtained from Prof. Antonius 
Rolink. All mice were housed in an optimized hygienic area with SPF (specific 
pathogen-free) rooms (in accordance with the guidelines of the Department of 
Biomedicine at the University Hospital Basel) and received acidified (pH 2.5) 
water and sterile food. Newborn male and female mice were separated 3 
weeks after birth in sterilized cages covered by a special protecting filter. No 
more than 5 mice were put together into each cage. 
 
4.1.2 INJECTIONS 
- Intravenous injection (i.v.): intravenous injections are given into one of the 
two tail veins. After putting mice under a heat lamp to increase blood flow, 
suspensions of at most 200 "l were injected into the lateral tail vein with a 
29G syringe (BD Micro-Fine, 0.5 ml, U-100 insulin) (Fig. 4.1). Quantities 
bigger than 200 "l were usually not injected, because they cause acute fluid 
overload and death.  
25 
 
- Intraperitoneal injection (i.p.): using a 1 ml syringe with a 26G needle, the 
skin and the abdominal muscles are pierced to inject the solution into the 
intraperitoneal cavity. Usually, 200 "l were injected into one mouse. The 
mouse is restrained and tilt so that the head is facing downward and its 
abdomen is exposed. The needle is inserted cranially into the abdomen at a 
30-45 degree angle caudal to the umbilicus and lateral to the midline (Fig. 
4.2). To test whether internal organs have been damaged, the syringe's 
plunger should be retracted before injecting the suspension: if vacuum has 
been created in the peritoneum, nothing has been damaged, but if a yellow 
fluid has been sucked into the syringe, the gut or other organs of the 
gastrointestinal tract have been damaged and the contaminated suspension 
has to be discarded.  
- Subcutaneous injection (s.c.):  s.c. injections were usually performed in two 
different body regions: in the inguinal area and in the footpad.  
Inguinal s.c injections were done to immunize mice for EAM induction (see 
“Emulsion preparation for mice immunization”). A 26G needle connected with 
a special Omnifix syringe (B. Braun, Melsungen, Germany) was inserted at 
the tail base through the skin, taking care to not break the peritoneum. After 
verifying that a vacuum was created retracting the syringe’s plunger, the 
emulsion was carefully injected and the needle was retracted only some 
seconds after the whole emulsion was injected. A subcutaneous pouch was 
visible in the inguinal region of the mouse. 
Figure 4.4. The direction of the 
needle relative to the foot (Lovik 
et al., 2007) 
Figure 4.3. Footpad injection in anesthetized mouse 




Figure 4.5 Equipment for isoflurane 
anesthesia. (Experimental Critical 
Care Medicine Lab, Valaperti and 
Germano)  
Footpad injections were performed to test the potential of different DC subsets 
to induce T cell differentiation in vivo. The advantage of this method is that 
foot’s draining lymph nodes are located in the popliteal region (Fig. 4.7), and 
almost all injected cells reach the popliteal LN (pLN). Only a small amount of 
footpad-injected cells bypasses the pLN and reaches other lymphnodes. For 
this reason we took advantage from the footpad injection to study T cell 
development in a well defined peripheral region. To perform footpad injection, 
suspensions were resuspended in a maximum volume of 50 "l, because 
higher volumes leak out of the foot. Mice were anesthetized with isoflurane 
and were provided with anesthesia during injection (Fig. 4.5). The cells were 
injected with a 29G needle inserted from the heel in the direction of the toes 
(Fig. 4.4). After injection, a subcutaneous bubble is visible in the footpad.  
 
- Isoflurane inhalation anesthesia: Mice 
were placed in a plastic container 
connected with a tube providing an 
anesthetic gas mixture. A vaporizer 
provided standardized gas concentration 
to the outlet tube. Isoflurane was 
administered in a mixture of N2O/O2. 
Anesthesia was induced by 2.5% 
vaporized isoflurane until loss of righting 
reflex (Fig. 4.5). After putting the animal 
on a stabile support for surgical operation 
(Fig. 4.3), anesthesia was maintained by 
direct inhalation of iso-vaporized 
isoflurane at a concentration of 1.5% 
during injection. During injection, treated 
mice did not move, did not have any 
reaction to pain stimuli, and their body temperature was kept constant at 





day 7 day 0 
Figure 4.6. schematic view of 
the inguinal region where 
mice are immunized for EAM 
induction. 
Figure 4.7. Overview of all LN. 
Nr. 10: mLN; Nr. 7: iLN; Nr. 9: 
pLN. (Van den Boek et al., 
2006) 
- Emulsion preparation for mice immunization: each mouse received 150 "g 
of peptide derived from "-myosin heavy chain (MyHC-", sequence 614-634 
Ac-RSLKLMATLFSTYASADR, CASLO, Denmark) emulsified in 100 "l of 
Complete Freud Adjuvant (CFA, 1 mg/mL, H37Ra, Difco Laboratories). 
Because MyHC-"-peptides are high static, they 
are weighted in a closed analytical balance 
(Mettler AE-260). Well-shaken CFA was pipetted 
directly on the weighted peptides in the balance 
with a 1-ml pipette, which is also used to 
properly resuspend peprides in CFA. After filling 
the mixed suspension into a syringe with a 
thread (Ominfix 2 ml, B. Braun, Germany) 
through an 18G needle, another syringe filled 
with the same amount of sterile phosphate saline 
buffer (PBS) is joined to the first one by fixing 
them in to a three ways stopcock (BD Connecta, 
Sweden). PBS is first pressed into the 
peptide/CFA suspension, and the emulsion is 
ready for use as soon as the resistance in the 
syringes is increased. Pouring some drops into 
water checks the quality of the suspension: if 
the suspension is correctly done, the drops 
maintain their shape and consistence, floating 
on the water’s surface.   
Mice were subcutaneously immunized at 6 to 8 
weeks of age on day 0 at one side of the tail 
base and boosted on day 7 on the other side 
(Fig. 4.6). No deaths were observed after 
immunization. 
 
4.1.3 LYMPH NODE ISOLATION 
Proper lymph node (LN) isolation is a 
prerogative to perform experiments with high 
28 
 
Figure 4.8. Localization of one of 
the two pairs of mLN in the thoracic 
cavity. Nr. 10: mLN; Nr. 11: 
tracheobronchal LN; a: lung (turned 
over); b: thymus (turned over). 
(Van den Broek et al, 2006). 
quality material. Organs should not be contaminated by other organs (for 
example parts of pancreas joined to the isolated spleen contain several 
enzymes that can interfere with the isolation of splenocytes), should not be 
damaged or broken, and surrounding organs should be intact (for example 
during mediastinal LN isolation, damaging the thymus can cause thymocytes 
contamination on the isolating mediastinal LN). Incorrectly isolated organs can 
compromise the validity of the results.   
- Mediastinal LN (mLN): mLN are located in 
the intrathoracic region. Two LN (bilaterally) 
are located lateral to the thymus along the 
internal thoracic artery and vein (Fig. 4.7). To 
extract them, the mouse is observed from 
the lateral side. Using tweezers, the lung and 
the thymus are carefully turned over to the 
opposite side (Fig. 4.8). Two LN surrounded 
by some fat are visible. With little curved 
tweezers, the two LN are gently extracted, 
taking care to not damage the thymus, which 
can contaminate the tweezers with high 
amounts of thymocytes. If the thymus is 
accidentally involved, extracted mLN and tweezers are cleaned in sterile PBS 
and resuspended in fresh sterile PBS.  
- Inguinal LN (iLN): iLN are located in the fold of the flank, near the deep 
circumflex of the iliac artery and vein. It is relatively easy to find them, 
because they are situated closed to the bifurcation of the superficial epigastric 
vein (Fig. 4.5). Sectioning the mice with a sagittal cut in the abdomen, 
continuing cutting toward the arms and the legs of the mice, it is possible to 
turn over the skin and see the iLN, which are carefully extracted with a little 
curved tweezers, avoiding to collect too much surrounding fat.  
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Figure 4.9. Localization of iLN (Nr. 7) and pLN (Nr. 9) 
in the hind limb region. (Van den Broek et al., 2006). 
- Popliteal LN (pLN): pLN are located in the popliteal fossa in the backside of 
the knee between the muscle biceps femuri and the muscle semitendinosus 
(Fig. 4.9). To harvest the pLN, a slit is made in the skin below the knee with 
scissors, and the skin is 
thereafter pulled upwards 
towards the thigh. With 
normal tweezers in one 
hand, the biceps femuri is 
lightly lifted up, while a little 
curved tweezers in the 
other hand is used to 
carefully extract the pLN. 
This step is really important, 
because the pLN are surrounded by high amounts of fat components that are 
almost round-shaped and misleading. In contrast to the white transparent 
color of the soft fat tissue, however, pLN have grey color and firm 
consistence, and a very constant location in the fork if a large branching 
artery. Properly extracted pLN sink when placed in medium, while fat tissue 
floats. This control is valid for all kind of extracted LN.    
- Spleen: with its length of approximately 1.5 cm, it is the easiest lymph organ 
to extract. It is localized in the left superior abdominal quadrant and has a 
lengthened, oval, and slightly curved shape. For extraction, the body of the 
spleen is held with tweezers and the hilum together with the gastrosplenic 
ligament is cut. Intact spleens can be kept on ice for several hours before 
meshing them to yield splenocytes. 
 
4.1.4 BLOOD COLLECTION 
As for humans, the total blood volume of the mouse makes up about 6-8% of 
its body weight (the body weight of a 8-12 weeks old mouse is between 25 
and 30 gram, meaning about 2 ml of blood). The blood was usually collected 
immediately after the mice have been killed form the inferior vena cava, using 
a 26G needle and a 1 ml syringe (Luer tuberculin, Primo Primo, Denmark). 
About 0.5 ml mouse blood was collected with this method. Mice should be 
quickly dissected, to avoid blood clotting, but carefully handled, to not break 
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any organ, which can bleed and reduce the yield. Mouse blood was collected 
and centrifuged for ten minutes at 10000 g in little tubes containing a gel (SST 
Tubes, BD Microtainer), which was of optimal density to separate blood cells 
from plasma.  
 
4.1.5 CHIMERA 
6 to 8 weeks old BALB/c CD45.2 mice were lethally irradiated with two doses 
of 6.5 Gy using a Gammatron (60Co) system, with a break of four hours 
between the two irradiations. Irradiated mice were reconstituted with a total of 
2x107 donor bone marrow cells, which were isolated from the bones of 
BALB/c CD45.1 mice. Femur and tibia were dissected, cleaned from all 
muscles, washed for one minute in 70% ethanol (only if no part of the bone 
was broken, because ethanol entering into the damaged bone could destroy 
many marrow cells), and put in PBS. The two extremities of each bone were 
cut and, with the help of a PBS-filled 10 ml syringe joined to a 26G needle, the 
bone marrow was flushed out of the bones. Marrow cells were filtered with a 
70 "l cell sieve, centrifuged, treated for two minutes with 2 ml/spleen of warm 
ACK to lysate red blood cells, washed with PBS, centrifuged, and 
resuspended in PBS at a concentration of 108 cells/ml. Donor BALB/c CD45.1 
bone marrow cells were injected i.v. into the lateral tail vein. Chimeric mice 
were housed in a specific pathogen free environment and received 
prophylactic antibiotics (0.2% Bactrim, Roche) in drinking water. Chimeric 
mice were used 2 month after reconstitution. 
 
4.2  Ex vivo cell cultivation 
 
4.2.1 BONE MARROW-DERIVED MACROPHAGES 
Bone marrow was isolated from 4-8 weeks old mice and prepared as 
described for chimera reconstruction. Six millions cells resuspended in 6 ml 
RPMI 1640 medium/10% FBS supplemented with 50 ng/ml macrophage 
colony stimulating factor (rmM-CSF, PeproTech) were seeded in 10 cm 
bacterial dishes (Ten-twenty-nine, Petri Dish, Falcon, BD) and cultured for 5 
days in an humidified incubator at 37°C containing 5% CO2. At day 1 and day 
3, 3 ml of medium were added. At day 5, macrophages surface markers were 
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analyzed by FACS. Mature bone marrow-derived macrophages (BMM) 
expressed CD11b, F4/80, CXCR4, CD11c, CD80 and MHC II. For in vivo 
experiments, BMM were stimulated for three hours with 0.1 "g/ml 
lipopolysaccharides (LPS) and 1 "g/ml recombinant mouse (rm) IFN-! 
(PeproTech). After washing, stimulated BMM were resuspended in PBS at a 
density of 107 cells/ml, and 2x106 cells/mouse were injected i.v. into the lateral 
tail vein. 
 
4.2.2 BONE MARROW-DERIVED DENDRITIC CELLS 
As for BMM, bone marrow was isolated from 4-8 old mice and prepared as 
described for chimera reconstruction. 2x106 bone marrow-derived dendritic 
cells (bmDC) were resuspended in 10 ml RPMI 1640 medium/10% FBS 
supplemented with 200 ng/ml granulocyte macrophage colony stimulating 
factor (M-CSF, PeproTech), seeded in 10 cm bacterial dishes (Ten-twenty-
nine, Petri Dish, Falcon, BD), and cultured at least for 8 days in an humidified 
incubator at 37°C containing 5% CO2. At day 3, 5 ml of medium containing 
GM-CSF are added, while at day 6 and day 8, 5 ml of supernatant were 
removed, centrifuged, resuspended in fresh medium, and added back into the 
dish. At day 8, non-adherent cells were collected by gently pipetting with cold 
PBS, resuspended in fresh medium containing GM-CSF, plated into a new 
dish at a density of 1.5x106 cells/ml, loaded with 10 "g/ml MyHC-"-peptide for 
1 hour, and stimulated for two additional hours with 0.1 "g/ml LPS and 5 
"g/ml anti-CD40 antibodies. PBS was used to detach and wash adherent 
bmDC, which were then resuspended at a density of 2.5x106 cells/ml for 
myocarditis induction. Aliquots of stimulated and non-stimulated bmDC were 
analyzed for the expression of surface markers such as CD11c, CD1b, MHC 
II, CD40, and CD80. Half a million of loaded and stimulated bmDC per mouse 
were injected i.p. three times at day 0, day 2, and day 4. Myocarditis severity 
scores peaked ten days after the first immunization.  
 
4.2.3 ISOLATION OF SPLENIC CD8"+ DENDRITIC CELL 
Because the percentage of dentritic cells (DC) in the mouse spleen is lower 
than 1%, mice were daily treated for ten days with 10 "g/mouse of 
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recombinant FLT3 ligand (FLT3L), promoting DC expansion. Treatment 
resulted in an increase of the percentage of DC up to 15-20% of all 
splenocytes. After FLT3L treatment, the spleen was dissected with sterile 
instruments and put in a 6 ml Petri Dish (Falcon, BD) containing 5 ml of 
Collagenase buffer (Collagenase buffer for 50 ml ddH2O: 0.119 g of 10mM 
Hepes-NaOH pH7; 0.4383 g of 150 mM NaCl; 0.018 g of 5 mM KCl; 0.047 g 
of 1 mM MgCl2; 0.00998 g of 1.8 mM CaCl2) supplemented with 185.2 "l of 
collagenase type IV (stock concentration: 27 mg/ml, Worthington, Lakewood, 
NJ). Using a 29G needle insulin syringe (0.5 ml, U-100 insulin, BD Micro-Fine) 
filled with collagenase solution, the spleen was injected twice in both 
extremities to properly digest all stroma cells. The spleen was then cut in 
small pieces with two sterile surgical blades (Swann-Morton, Sheffield, 
England) and incubated for 40 minutes at 37°C. Immediately after incubation, 
PBS supplemented with 1% FBS and 2 mM EDTA was added to block the 
digestion. The dish was properly washed with cold PBS to collect all cells, 
and, if necessary, also scratched with a cell scraper (16 cm, Sarstedt, 
Newton, NC) to detach adherent DC. Cell suspension was mashed up 
through a 70 "m cell strainer (BD Falcon) with the plunger of a 1 ml tuberculin 
syringe. After centrifugation, red blood cells were lysed with 2 ml of warm 
ACK for two minutes. Splenocytes were resuspended in PBS, centrifuged, 
filtered through a 40 "m cells strainer (BD Falcon), centrifuged again, and 
resuspended in 200 "l MACS buffer (PBS supplemented with 1% FBS and 2 
mM EDTA, sterile filtered) for each 108 splenocytes. This is the optimal 
amount of buffer for Microbeads labeling. Splenocytes were incubated for ten 
minutes on ice with a biotin-antibody cocktail staining for B cells (CD45R), T 
cells (CD90), and natural killer cells (CD49b) (CD8+ Dendritic Cell Isolation 
Kit, mouse, MACS, Miltenyi Biotec, Bergisch Gladbach, Germany). This 
staining allows a depletion of unwanted cells, increasing the frequency of DC 
among the splenocytes. 150 "l of MACS buffer for each 108 cells were added, 
and immediately 100 "l of anti-biotin Microbeads were mixed together. After 
15 minutes incubation on ice, cells were washed, centrifuged, and 
resuspended in 500 "l of MACS buffer for each 108 cells. The cell suspension 
was ready for depletion using an autoMACS Separator (Miltenyi Biotec, 
Bergisch Gladbach, Germany), which was rinsed and cleaned according to 
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the provider. Selecting the depletion program “Depl025” and waiting for about 
twenty minutes, a more pure DC population was collected from the negative-
depleted outlet port. After quick washing, negative-depleted cells were 
resuspended in 400 "l of MACS buffer for each 108 initial cells together with 
100 "l of CD8"+ Microbeads and incubated for 30 minutes on ice. After 
washing, the cells were resuspended in 500 "l for each 108 initial cells and 
positively sorted selecting the program “Posseld2” of the autoMACS 
Separator. Sorted CD8"+ DC were quickly washed with MACS buffer and 
resuspended in RPMI 1640 medium/1% NMS for cell counting. CD8"+ DC 
were seeded in 6 ml Petri Dish (Falcon BD) at a concentration of 1.5x106 
cells/ml, loaded with 2 "g/ml MyHC-"-peptide and stimulated with either 50 
ng/ml tumor necrosis factor alpha (TNF-", PeproTech) or 0.1 "g/ml LPS plus 
5 "g/ml anti-CD40 antibodies for 4 hours. After incubation, DC were washed 
with cold PBS, if necessary scratched with a cell scraper to detach adherent 
cells, centrifuged, and resuspended in PBS at a concentration of 2.5x106/ml. 
Each vaccinated mouse received 0.5 Mio loaded and stimulated CD8"+ DC 
by i.v. injection three times, that is every second day. 
 
4.2.4 MYHC-"-SPECIFIC CD4+ T-CELL LINES 
CD4+ T cells were sorted and purified from the spleens of diseased mice 
digested as described in “Isolation of splenic DC”. Splenocytes suspension    
was resuspended in 0.5 ml MACS buffer and incubated with 50 "l anti-CD4 
Microbeads (Miltenyi, Bergisch Gladbach, Germany) for 15 minutes at 4°C. 
After incubation, stained cells were washed, centrifuged, and resuspended in 
0.5 ml MACS buffer for cell sorting. Choosing the program “Posseld2” in the 
autoMACS Separator, five minutes later CD4-labelled splenocytes were 
separated and collected from the “pos2” outlet port. Purified CD4+ T cells 
were quickly washed, centrifuged, resuspended in 5 ml RPMI 1640/10% FBS, 
and cultured in a 6 well plate (Falcon, BD) with irradiated (25 Gy) splenocytes 
at a 1:2 ratio in the presence of 2 "g/ml MyHC-" for 7 days. Cells were then 
washed and rested in the presence of 20 ng/ml IL-2 (PeproTech) and either 
10ng/ml IL-12p70 (PeproTech) and 1 "g/ml anti-IL-4 (self-produced), or 10 
ng/ml IL-23 (eBiosciences), 1 "g/ml anti-IL-4, and 0.1 "g/ml anti-IFN-
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! (PeproTech) for another 7 days. We used either recombinant mouse 
cytokines or anti-murine antibodies. This pulse/rest cycle was repeated at 
least three times. After three cycles, CD4+ T cell clones were stimulated for 4 
hours with 20 ng/ml phorbol myristate acetate (PMA), 1 "M ionomycin (IO), 
and 10 "g/ml Brefeldin A (BFA) (all Sigma) for analysis of intracellular 
cytokines production by FACS. Production of IFN-!, IL-4, and IL-17 were 
parameters used to characterize CD4+ Th1, Th2, and Th17 cell lines, 
respectively. Finally, CD4+ T cells were re-stimulated on MyHC-" pulsed APC 
for 4 days before i.p. injection of 107 cells into syngeneic wild-type or RAG2-/- 
recipient mice. Myocarditis develops after 10-15 days. 
 
4.2.5 ISOLATION OF HEART INFILTRATING CELLS 
Hearts were gently perfused with 10 ml of fresh PBS using a 26G needle and 
a 10 ml syringe, dissected with scissors, placed in a 6 ml Petri Dish containing 
20 "g/ml Liberase Blendzyme (Roche), cut in small pieces with two sterile 
surgical blades, and digested for 45 minutes at 37°C. Digested hearts were 
resuspended in PBS supplemented with 1% FBS and 2 mM EDTA to block 
the enzymes, mashed up on a 70 "m cell strainer (BD Falcon) with the help of 
the plunger of a 1 ml syringe, centrifuged at 50 g for two minutes to pellet 
unwanted cardiomyocytes, passed again through a 40 "m cell strainer, 
centrifuged, and finally passed through a 15 "m self-assembled strainer 
(Sefar AG). Cell suspension was resuspended in 1 ml/heart of FACS buffer 
(PBS supplemented with 0.5% bovine serum albumin and 2 mM EDTA, 
filtered) for analysis of surface markers. 
 
4.3  In vitro experiments 
 
4.3.1 PROLIFERATION ASSAY 
CD4+ T cells were purified as described in “MyHC-"-specific CD4+ T-cell 
lines”. 5x104 sorted CD4+ T cells were resuspended in 200 "l RPMI 1640/10% 
FBS and re-stimulated in a 96 well plate (U-Bottom, Falcon, BD) on 105 
irradiated (25 Gy) syngenic splenocytes pulsed with 2 "g/ml MyHC-"-peptide 
for 48 hours. For peptide-unspecific stimulation, 200 "l anti-CD3 and anti-
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CD28 (both 1 mg/ml, BD Biosciences) resuspended in PBS were incubated 
for 2 hours at 37°C into 96 well plate. After washing and centrifuging, 5x104 
CD4+ T cells were incubated for 48 hours. Titrating amounts of BMM were co-
cultured with peptide-specific or peptide-unspecific stimulated CD4+ T cells. 
Eight hours before the incubation is finished, 0.5 "Ci [3H]-thymidine 
(PerkinElmer, Boston, MA) were added into each well. The cells were then 
passed through special 96 well filters (UniFilter-96, GF/C, PerkinElmer), 
washed with 70% ethanol, treated with a scintillation buffer (Microscint 20, 
PerkinElmer), covered with an adhesive sealing film (TopSeal-A, 96-well 
microplates, PerkinElmer), and analyzed for fluorescence in a TopCount-NXT 
(Packard). Incorporation was measured as a read-out for proliferation 
responses. 
 
4.3.2 CELL LABELING 
Cells were labeled to monitor migration and proliferation of cells injected into 
mice. The most stable intracellular fluorescent dye was carboxyfluorescein 
diacetate succinimidyl ester (CFSE, Molecular Probes), used at an optimized 
final concentration of 1 "M for BMM. Mature BMM were resuspended in PBS 
supplemented with 5% FBS and 1X penicillin/streptomycin at a concentration 
of 2x106 cells/ml. 110 "l of 10 "M CFSE were rapidly added to each ml of 
BMM and quickly vortexed to uniformly distribute the dye to all cells. After five 
minutes incubation at room temperature, the cell suspension was washed 
three times with 10 volumes of PBS/5% FBS and centrifuged at room 
temperature.  Labeled BMM were injected intravenously at 2x106 cells per 
mouse on days 7, 9, and 11 after the first immunization.  
For IL-17 depletion, which was performed in the same experiments, 
neutralizing antibodies against IL-17 (R&D Systems), or its isotype control 
antibody (rat IgG2A) were injected i.p. every second day at a dosage of 50 "g 
per mouse. Mice were killed at day 14 and hearts were analyzed for infiltrating 
CFSE-labeled BMM. 
 





Cell suspensions were stained using fluorochrome-conjugated mouse-specific 
antibodies. Following fluorochromes were used: Pacific Blue™, excited by the 
UV-laser light (405 nm), 455 nm emission maximum; Fluorescein 
isothiocyanate (FITC), excited by the argon laser light (488 nm), 525 nm 
emission maximum; Phycoerythrin (PE), excited by the argon laser light, 575 
nm emission maximum; Peridinin Chlorophyll Protein (PerCP), excited by the 
argon laser light, 675 nm emission maximum; Phycoerythrin/Cyanine 5.5 
(PE/Cy5.5), a tandem conjugate dye, excited by the argon laser light, 690 nm 
emission maximum; Peridinin Chlorophyll Protein/Cyanine 5.5 (PerCP/Cy5.5), 
a tandem conjugate dye, excited by the argon laser light, 690 nm emission 
maximum; Phycoerythrin/Cyanine 7 (PE/Cy7), a tandem conjugate dye, 
excited by the argon laser light, 774 nm emission maximum; 7-amino-
actinomycin D (7AAD), a viability dye and ready-to-use reagent combining 
between bases of the DNA, excited by the argon laser light, 647 nm emission 
maximum; Allophycocyanin (APC), excited by the helium/neon (He/Ne, 
633/635 nm) laser light, 660 nm emission maximum.  
Following antibodies were titrated and used at the corresponding 
concentration (optimized for CyAN ADP Flow Cytometer, Dako):  
Surface staining: CD3$-FITC, 1:400; CD3$-PE/Cy7, 1:1200; CD4-APC, 1:600; 
CD11b-APC, 1:600; CD11c-APC, 1:600; CD11c-PE, 1:300; CD14-
biotinylated, 1:300; CD19-APC, 1:600; CD25-PE, 1:1000 CD31-FITC, 1:300; 
CD40-FITC, 1:300; CD44-FITC, 1:300; CD45.1-FITC, 1:400; CD45.2-FITC, 
1:400; CD45.2-PerCP, 1:300; CD45-PE, 1:300; CD49b-APC, 1:1200; CD62L-
PE, 1:300; CD69-PE, 1:300; CD80-FITC, 1:300; CD86-FITC, 1:300; MHC II (l-
Ad)-FITC, 1:1200; CXCR4-FITC, 1:400; F4/80-PE, 1:400; GITR-PE/Cy7, 
1:800; Gr-1 (Ly6G/C)-FITC, 1:400; AnnexinV-PE, 1:200; 7AAD, 1:200; 
Streptavidin-PerCPCy5.5, 1:400; Streptavidin-APC, 1:600.  
Round-bottom 96 well plates were used to perform both surface and 
intracellular staining. Staining for FACS analysis starts with the labeling of 
surface markers. 5x105 cells/well were resuspended in 200 "l/well FACS 
buffer (PBS supplemented with 0.5% BSA and 2 mM EDTA), centrifuged at 
2000 rpm (Heraeus, Multifuge 4kr), resuspended in 200 "l/well of FACS buffer 
supplemented with 1:50 NMS to block unspecific bindings, and incubated for 
15 minutes at 4°C. In the meantime, antibodies were properly diluted in FACS 
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buffer. After centrifugation, cells were resuspended in 50 "l/well of prepared 
antibodies according to the protocol, incubated for 15 minutes at 4°C, washed 
three times with 200 "l/well, and resuspended in either 400 "l FACS buffer for 
acquisition or 200 "l 4% paraformaldehyde for intracellular staining. 
Antibodies for intracellular staining (concentrations optimized for CyAN ADP 
Flow Cytometer, Dako): IFN-!-PacificBlue, 1:400; IFN-!-PE, 1:1000; IL-4-PE, 
1:400; IL-6-FITC, 1:600; IL-6-PE, 1:300; IL-10-PE, 1:300; IL-12p70-PE, 1:300; 
IL-12p70-PECy5.5, 1:700; IL-17A-FITC, 1:800; IL-17A-PE, 1:400; TNF-"-
FITC, 1:1000; FoxP3-FITC, 1:50, NOS2, 1:75; chicken anti-rabbit-Alexa488, 
1:100. Antibodies were purchased from BD Pharmingen, eBiosciences, or 
BioLegend.  
Prior to intracellular staining, cells were re-stimulated for 4 hours with 20 
ng/ml PMA, 1 "M ionomycin, and 10 "g/ml Brefeldin A (all Sigma). After 
surface staining, cells were fixed with 4% paraformaldehyde for 20 minutes at 
4°C, washed twice with 200 "l 0.5% saponin buffer (FACS buffer 
supplemented with 0.5% saponin (Sigma)), and resuspended with 200 "l 
0.5% saponin buffer for 15 minutes at 4°C. In the meantime, antibodies were 
properly diluted in 0.5% saponin buffer. After centrifugation, cells were 
resuspended in 50 "l/well of prepared antibodies according to the protocol, 
incubated for 30 minutes at 4°C, washed three times with 200 "l/well 0.5% 
saponin buffer, washed for the last time with FACS buffer to close the cell 
membranes, and resuspended in 400 "l FACS buffer for acquisition.  
Samples were acquired with a CyAN ADP Flow Cytometer (Dako) until at 
least 200000 events, collected from a live gate using forward/side scatter 
plots, and then analyzed using FlowJo (TreeStar) software.  
 
4.4.2 ELISA AND GRIESS REACTION 
Supernatants of various cultivated cells were collected, centrifuged for 10 
minutes at 3 g in a table centrifuge (Eppendorf), and either quickly frozen at -
80°C or directly used for ELISA. Cytokine levels were measured using 
commercially available ELISA kits for IL-1# (PeproTech), IL-6 (PeproTech), 
IL-17 (Quantikine, R&D Systems), IL-23 (eBiosciences), IFN-! (Quantikine, 
R&D Systems), TGF-# (Quantikine, R&D Systems), and TNF-" (Quantikine, 
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R&D Systems). In general, ELISA-plates were incubated overnight with 
coating antibodies, washed several times with washing buffer, blocked with 
blocking buffer supplemented with FBS or BSA, and washed again at least 
four times. Serial dilutions were performed for the standard curve and 
supernatants of interest were usually diluted 1:2 to 1:10. After incubation of 2 
hours, the plate was washed several times and avidin-loaded detecting 
antibodies were incubated for 1 hour. The plates were washed again several 
times and horseradish peroxidase reacting with the avidin was incubated for 
30 minutes. After washing, a substrate was added, incubated for 30 minutes 
and blocked for plate reading.  
Nitrite (NO2
-) levels reflecting NO production in culture supernatants were 
assessed using a colorimetric assay based on the Griess reaction (Promega). 
50 "l supernatant reacted with 50 "l sulfanilamide solution for 10 minutes. 
After a second reaction with 50 "l NED (N-1-napthylethylenediamine 
dihydrochloride) developed a purple-magenta color, the plates were ready for 
plate reader with a filter between 520 and 550 nm. 
 
4.4.3 QUANTITATIVE RT-PCR 
Hearts were dissected and put without previous perfusion in a 15 ml tube 
(non-pyrogenic, Sarstedt) filled with 1 ml Trizol™ reagent (Invitrogen). With a 
sonicator, heart tissue was homogenized after 5 cycles of 6 seconds, with a 
break of 10 seconds between each cycle. Importantly, sonication was 
performed on ice, as this homogenization process produced high quantities of 
heat. RNA was then isolated adding 0.1 ml bromochloropropane and 
centrifuging at 12000 g for 15 minutes at 4°C, precipitated adding isopropanol 
and vigorously mixing, washed using 75% ethanol, and resuspended adding 
100 "l ddH20. 2"g RNA were used to perform a reverse transcriptase reaction 
to produce cDNA. RNA was mixed with 1 "l oligo dT primer (Invitrogen), 
incubated for 5 minutes at 70°C, put on ice for 4 minutes, and spun down. 7.5 
"l of a master mix containing dNTPs, reverse transcriptase, ribonuclease 
inhibitors, and a buffer, were added and transferred in little PCR tubes for the 
reaction.  
After cDNA synthesis, real-time PCR was performed with SYBR Green 
(Applied Biosystems), using a 7500 Fast Real time PCR System (Applied 
39 
 
Biosystems) with GAPDH as an internal control. The following primers were 
used: SDF-1 Fw 5’-CGT GAG GCC AGG GAA GAG-3’ Rv 5’-TGA TGA GCA 
TGG TGG GTT GA-3’, MCP-1 Fw 5’-CAT CAC TGA AGC CAG CTC TCT CT-
3’ Rv 5’-GCA GGC CCA GAA GCA TGA-3’, MIP-1a Fw 5’-TTT TGA AAC 
CAG CAG CCT TTG-3’ Rv 5’-TCT TTG GAG TCA GCG CAG ATC-3’, 
GAPDH Fw 5’-CCT GCA CCA CCA ACT GCT TA-3’ Rv 5’-TCA TGA GCC 
CTT CCA CCA TG-3’. 
 
4.5  Statistics 
 
The Mann-Whitney U test was used for the evaluation of severity scores. 
Dichotomous data were analyzed using Fisher’s exact test. Normally 
distributed data, such as proliferation responses and cytokine levels were 
compared using ANOVA and Student’s t-test. Statistical analysis was 





5  Results 
  
5.1  Th17, but not Th1 cells, are pathogenic in the EAM model  
Experimental autoimmune myocarditis is a CD4+ T cell-mediated disease 
(17). Nevertheless, adoptive transfer of in vitro re-stimulated CD4+ T cells 
isolated from diseased mice usually results in low disease scores in SCID, 
RAG2-/- or LPS pretreated wild-type recipients (111, 112). Based on the 
hypothesis that CD4+ Th17 cells represent the pathogenic subpopulation of 
heart-specific CD4+ Th cells, we isolated CD4+ Th cells from draining lymph 
nodes of diseased mice and expanded them in vitro by repetitive and 
alternating rounds of re-stimulation on MyHC-"-loaded irradiated antigen-
presenting cells followed by a resting phase in either IL-12p70/anti-IL-4 or IL-
23/anti-IL-4/anti-IFN-! containing medium. Depending on these culture 
conditions, we generated MyHC-"-specific CD4+ Th cell lines with either a 
Th1, or Th17 phenotype (Fig. 5.1A). Importantly, both Th1 and Th17 cell lines 
showed comparable in vitro proliferation responses after 72 hours of re-
stimulation with the MyHC-" antigen on irradiated APC (Fig. 5.1B).  
To compare the capacity of the MyHC-"-specific Th1 and Th17 T cell lines to 
Figure 5.1. CD4+ Th17 cells, but not CD4+ Th1 cells, induce EAM. A, Characterization of 
MyHC-"-specific Th17 and Th1 cell lines. B, MyHC-"-specific Th17 (!) and Th1 (") cell lines 
show comparable in vitro proliferation on irradiated MyHC-"-pulsed splenocytes. Proliferation 
was assessed by measurement of 3H-thymidine incorporation. C, Disease severity socres of 
individual mice adoptively transferred with 107 MyHC-"-specific Th17 cells (!) vs. MyHC-"-




induce autoimmune myocarditis, groups of age and sex matched wild-type 
BALB/c mice were injected with 107 CD4+ T cells/mouse. As illustrated in Fig. 
5.1C, only CD4+ Th17 cells, but not CD4+ Th1 cells, induced autoimmune 
myocarditis.   
Of note, increasing the numbers of the transferred Th17 cells increased 
average myocarditis scores (figure not shown). In contrast, Th1 cell treated 
mice were protected from myocarditis (Fig. 5.1C) and transfer of up to 108 
CD4+ Th1 cells per mouse induced only minimal pericarditis, and some non-
specific increase in the numbers of perivascular mononuclear cells.  
Taken together these findings illustrate the direct pathogenic role of MyHC-"-
specific CD4+ Th17 cells. In contrast, MyHC-"-specific CD4+ Th1 cells do not 
mediate autoimmune myocarditis. 
 
5.2  IL-17 is critical for the recruitment of CD11b+ monocytes to the heart 
Inflammatory infiltrates in EAM mainly consist of monocytes, granulocytes and 
some activated CD4+ T cells (113). As illustrated in Fig. 5.2, MyHC-"/CFA 
immunization resulted in a 3 to 4 fold increase of CD45+ cells in hearts of 
diseased mice, compared to control hearts of CFA injected control mice. 
Analysis of immunized CD45.1/CD45.2 chimeras confirmed that heart- 
infiltrating CD45+ cells were from host bone marrow (Fig. 5.2). Importantly, the  
Figure 5.2. CD11b+ monocytes are bone marrow-derived and reflect the major 
population of heart-infiltrating leukocytes in EAM. Heart-infiltrating cells were isolated 
from hearts of CD45.1/CD45.2 chimeric mice 21 days after either MyHC-"/CFA or CFA 




vast majority of heart-infiltrating leukocytes expressed CD11b+ and included a 
minority of CD11b+F4/80+ macrophages (Fig. 5.2), some CD11b+Gr-1high 
granulocytes, and CD11b+CD11c+ dendritic cells (not shown). Based on 
reports that IL-17 promotes the recruitment of blood monocytes to inflamed 
organs (22), we therefore decided to specifically address the effect of IL-17 on 
the recruitment of CD11b+ monocytes to the inflamed heart in the EAM model. 
As illustrated in Fig. 5.3A, we first compared the release of IL-17 from in vitro 
re-stimulated, heart-infiltrating T cells of immunized wild-type BALB/c mice at 
the peak of disease at day 21, and at day 30 after resolution of most of the 
inflammatory infiltrates. As shown in Fig. 5.3B, histological disease severity 
scores parallel IL-17 release from heart-infiltrating T cells. Next, we treated 
groups of MyHC-"/CFA immunized mice every second day for 21 days with 
either an IL-17 blocking antibody, or an isotype control Ig. As illustrated in Fig. 
5.3C, anti-IL-17 treatment markedly reduced the gross disease severity 
scores, confirming a direct pathogenic role of IL-17 in EAM.  
To directly assess the relevance of IL-17 in the recruitment of CD11b+ 
monocytes to the inflamed heart in vivo, we generated immature, 
CD11b+CXCR4+Gr-1low co-expressing monocytes (Fig. 5.3D) from bone 
marrow, and labeled the cells with CFSE. 2x106 CFSE-labeled CD11b+ 
monocytes were then injected intravenously at day 14 post immunization in 




Figure 5.3. A, IL-17 production of heart-infiltrating T cells. 105/ml of infiltrating CD3+ cells 
were isolated from diseased hearts of wild-type mice, 21 or 30 days after MyHC-" 
immunization, and re-stimulated with anti-CD3/anti-CD28 for 24 hours. IL-17 was measured in 
supernatants using commercially available ELISA kits. *p = 0.0071.  
B, Disease severity scores of individual, MyHC-"/CFA-immunized wild-type mice at days 21 
and 30. *p = 0.0023.  
C, Anti-IL-17 treatment reduces myocarditis severity in MyHC-"/CFA immunized wild-type 
mice. Mice were immunized with 150 µg MyHC-"/CFA and injected with either 50 µg anti-
mouse IL-17 or isotype antibody every second day. Mice were sacrificed on day 21. Individual 
disease scores (*p = 0.0092), X25 and X200 original magnifications are shown.  
D, Surface molecule expression patterns of bone marrow-derived CD11b+ monocytes 
representing an immature population.  
E, Anti-IL-17 treatment blocks recruitment of CFSE-labeled CD45+CD11b+ cells to the heart. 
Heart-infiltrating cells were isolated at day 15 from immunized wild-type mice injected with 
CFSE-labeled wild-type CD11b+ monocytes, 24 hours after either anti-IL-17 injection (red line) 
or isotype antibody injection (blue line). The grey area represents CD45+CD11b+ cells of 
untreated immunized wild-type mice injected with unlabeled wild-type CD11b+ cells. The 
histogram is gated on CD11b and CD45 expressing cells. 
F, Anti-IL-17 treatment suppresses SDF-1, MCP-1, and MIP-1a expression in heart tissues of 
immunized wild-type mice. Relative expression of SDF-1, MCP-1, and MIP-1" mRNA in 




Figure 5.4. A, Cytokine production profile of MyHC-" specific CD4+ T cells. CD4+ cells were 
isolated from lymphnodes of diseased wild-type mice, and re-stimulated on irradiated 
splenocytes in the presence (black bars) or absence (white bars) of 2 µg/ml of MyHC-" for 48 
hours. The indicated cytokines were measured using supernatant ELISA. *p < 0.05.  
B, CD11b+ monocytes suppress proliferation of autoreactive CD4+ T cells. CD4+ cells from 
diseased wild-type mice were re-stimulated on irradiated splenocytes pulsed with either 2 
µg/ml of MyHC-" (black bars) or anti-CD3/anti-CD28 (white bars) in the presence of titrating 
amounts of bone marrow derived wild-type CD11b+ monocytes. Proliferation responses are 
expressed as percentages (mean±SD from 5 culture wells) compared to an average standard 
value representing proliferation in the absence of CD11b+ monocytes.  
C, The suppressive effects of CD11b+ monocytes require close contact to APCs and T cells. 
Wild-type CD4+ T cells were MyHC-" re-stimulated on irradiated APC in the presence of 2.5 x 
103 wild-type CD11b+ monocytes, which were either in contact with the CD4+ T cells/APC or 
separated by culture well inserts. 
D, Nitric oxide release parallels the reduced proliferation of CD4+ T cells in the presence of 
CD11b+ monocytes. CD4+ T cells from diseased wild-type mice were MyHC-" re-stimulated 
on irradiated APC in the presence of 2.5 x 103 CD11b+ monocytes. Nitrite (NO2
-) levels 
reflecting NO production in culture supernatants were assessed using a colorimetric assay 
based on the Griess reaction.  
E, Addition of the NOS inhibitor L-NAME, but not its inactive enantiomer D-NAME, restores 
proliferation in the presence of CD11b+ monocytes. CD4+ T cells from diseased wild-type mice 
were MyHC-" re-stimulated on irradiated APC in the presence (white bars) or absence (black 
bars) of 2.5 x 103 CD11b+ monocytes.  
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either an IL-17-blocking antibody or an isotype control antibody. Twenty-four 
hours later, the relative numbers of CFSE-labeled CD11b+ cells were 
analyzed in hearts of treated mice. FACS analysis of heart infiltrating cells 
from anti-IL-17-treated mice showed no CFSE-labeled CD11b+ monocytes 
within the CD45+CD11b+ gate. In contrast, CFSE+ cells were detected in 
suspensions of heart infiltrating cells isolated from isotype treated controls 
(Fig. 5.3E).  
To address the question how anti-IL-17 treatment affects the recruitment of 
CD11b+ monocytes we compared mRNA expression of two cytokines, known 
to mediate monocyte/macrophage recruitment in EAM (114). As illustrated in 
Fig. 5.3F, anti-IL-17 treatment markedly reduced MIP-1" and MCP-1 mRNA 
expression in hearts of immunized mice.  
Taken together, our findings confirm the critical role for IL-17 in the 
recruitment of CD11b+ bone marrow-derived monocytes, the predominant 
heart-infiltrating cell population, to the heart in the EAM model.  
 
5.3  CD11b+ monocytes suppress CD4+ T cell proliferation  
As mentioned previously, we consistently observed spontaneous disease 
regression in diseased wild-type mice after a peak of histological severity 
scores at day 21 after immunization. Given the fact that most of the infiltrating 
cells belong to the CD11b+ monocyte fraction (Fig. 5.2), we next asked how 
these cells interact with heart-specific, autoreactive T cells. Accordingly, we 
isolated CD4+ T cells from lymph nodes and spleens of mice with autoimmune 
myocarditis, and re-stimulated for 72 hours on irradiated splenocytes pulsed 
with the MyHC-" self-antigen. Of note, in vitro MyHC-" re-stimulated CD4+ T 
cells from diseased mice comprise a heterogeneous population of IL-4, IFN-!, 
IL-2, IL-10 and IL-17 producing cells (Fig. 5.4A). As illustrated in Fig. 5.4B, the 
in vitro proliferation of CD4+ T cells isolated from mice with autoimmune 
myocarditis was markedly reduced on MyHC-"-pulsed, irradiated antigen-
presenting cells, if titrated numbers of syngenic CD11b+ monocytes were 
added to cell culture wells. As illustrated in Fig. 5.4C, close contact between 
CD11b+ monocytic cells and T cells was critical for the observed inhibition of T 
cell proliferation, as culture well inserts separating T cells/antigen-presenting 
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Figure 5.5. A, CD11b+ monocytes suppress CD4+ T cell responses reversibly. Wild-type 
CD4+ cells were re-stimulated on irradiated splenocytes pulsed with 2 µg/ml of MyHC-" in the 
presence (white bar, left) or absence (black bar, left) of 2.5 x 103 CD11b+ monocytes. After 48 
hours, CD4+ T cells were isolated, washed, and recovered for 4 days in fresh medium 
containing 20 U/ml IL-2, before re-stimulation for another 48 hours on MyHC-"-pulsed APC in 
the absence of CD11b+ monocytes (black and white bars, right). Proliferation responses are 
expressed as percentages compared to an average standard value representing proliferation 
of CD4+ T cells on APC only.  
B, CD11b+ monocytes lacking the IFN-! receptor do not suppress CD4+ T cell proliferation. 
CD4+ T cells from diseased wild-type mice were re-stimulated on irradiated APC in the 
presence of either IFN-!R-/- monocytes (white bars) or IFN-!R+/+ monocytes (black bars). 
Proliferation responses are expressed as percentages compared to an average standard 
value representing the proliferation of CD4+ T cells on APC in the absence of monocytes.  
C, CD11b+ monocytes suppress proliferation of MyHC-"-specific Th1 cell lines but not Th17 
cell lines. 5 x 104 MyHC-"-specific CD4+ Th1 (black bars) and Th17 (white bars) cells were re-
stimulated on irradiated APC pulsed with 2 µg/ml MyHC-" in the presence of titrating amounts 
of CD11b+ monocytes for 72 hours. Proliferation responses are expressed as percentages 
compared to an average standard value representing proliferation of CD4+ Th17 cells on APC 
only. 
D, IFN-! triggers the suppressive effects of IFN-!R+/+ but not IFN-!R-/- CD11b+ monocytes on 
CD4+ Th17 cell proliferation. MyHC-" specific Th17 T cell lines were re-stimulated on 
irradiated MyHC-"-pulsed APC in the presence of 2.5 x 103 either IFN-!R+/+ (white bars) or 




cells and CD11b+ monocytic cells prevented the suppression of the 
proliferation response. These results show that the CD11b+ monocyte-
mediated effect requires close contact of CD11b+ monocytes to T cells. 
Similar results were obtained if CD4+ T cells were re-stimulated with plate 
bound anti-CD3/anti-CD28 (Fig. 5.4B). The latter findings largely exclude a 
relevant role of the antigen-presenting cells in the CD11b+ monocyte-
mediated T cell suppression mechanism.  
 
5.4  CD11b+ monocytes release nitric oxide suppressing T cell proliferation  
As shown previously, the CD11b+ monocyte-mediated effects require close 
contact of CD11b+ monocytes to T cells. This observation argues for either a 
short-lived soluble mediator or direct cell-cell interaction. We first looked for a 
short-lived, soluble mediator and analyzed nitrite levels reflecting nitric oxide 
production in supernatants of APC/T cell/ CD11b+ monocyte co-cultures. Nitric 
oxide had been shown to mediate suppression of T cells (49). As illustrated in  
 
Figure 5.6. IFN-! enhances nitric oxide 
release from CD11b+ monocytes mediating 
Th17 T cell suppression. MyHC-"-specific 
CD4+ Th17 cell lines were re-stimulated on 
irradiated, MyHC-"-pulsed APC in the 
presence or absence of 2.5 x 103 CD11b+ 
monocytes together with either 5 ng/ml of 
recombinant mouse IFN-!, 0.1 µg/ml LPS, or 
IFN-!/LPS. Proliferation responses are 
expressed as percentages compared with an 
average standard value representing 
proliferation of CD4+ T cells on APC only. 
Nitrite (NO2
-) levels reflecting NO production in 
culture supernatants were assessed using a 
colorimetric assay based on the Griess 
reaction.  
 
Fig. 5.4D, the addition of CD11b+ monocytes to T cell/APC cultures indeed 
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resulted in greatly enhanced nitric oxide release. The decisive role of nitric 
oxide in suppressing activated CD4+ T cells was finally confirmed by the 
observation that the T cell suppressing effects of the CD11b+ monocytes 
disappeared in the presence of the non-specific NOS inhibitor L-NAME. In 
addition, adding titrating numbers of paraformaldehyde fixed CD11b+ cells to 
T-cell/APC cultures did not affect T cell proliferation (not shown). Together 
with the complete reversibility of the suppressive effect of the CD11b+ 
monocytes on the T cell proliferation in the presence of the NOS inhibitor L-
NAME, we conclude that release of nitric oxide explains the suppressive 
effects of the CD11b+ monocytes in our proliferation assays.  
To analyze the reversibility of the nitric oxide-mediated T cell suppression, we 
recovered T cells from monocyte/APC/T cell co-cultures and expanded them 
in fresh medium in the presence of IL-2. As illustrated in Fig. 5.5A, recovered 
and purified CD4+ T cells again proliferated, if MyHC-" loaded APC were 
added in the absence of CD11b+ monocytes, confirming the reversibility of the 
suppressive effect. 
 
5.5  IFN-! triggers NO-mediated T cell suppression by CD11b+ monocytes  
IFN-! has been recognized as a major NOS2 inducer in macrophages. 
Accordingly, CD11b+ monocytes lacking the interferon gamma receptor did 
not suppress T cell proliferation (Fig. 5.5B). The question therefore arises 
whether the CD11b+ monocyte mediated T cell suppression also affects CD4+ 
Th17 cells, the major pathogenic T cell population in EAM. In fact, and as 
illustrated in Fig. 5.5C, the proliferation of CD4+ Th17 cells was not affected 
by the addition of titrating numbers of wild-type CD11b+ monocytes on IFN-!R-
/- antigen-presenting cells. In contrast, the proliferation of CD4+ Th1 cells was 
markedly reduced. Adding IFN-!, however, promoted the release of nitric 
oxide in culture sups and inhibited CD4+ Th17 cell proliferation (Fig. 5.5, B & 
D, Fig. 5.6). Of note, this effect was independent of the presence of the IFN-
!R on the CD4+ Th17 cell line (not shown). Taken together these findings 
show, that IFN-! directly acts on the CD11b+ monocytes and triggers 




Figure 5.7. A, Patterns of heart-infiltrating CD45+ cells in diseased IFN-!R+/+ (black bars) and 
IFN-!R-/- (white bars) mice. Heart-infiltrating cells were isolated from groups of mice 21 and 30 
days after MyHC-"/CFA immunization, stained for CD45, and either CD11b, F4/80, CD11c, 
Gr-1, or CD3 and analyzed by flow cytometry. The left graph illustrates CD45+ cells as % of 
total cells on day 21 and day 30. The right graph shows the pattern of infiltrating cells as % of 
CD45+ cells at day 21 in wild-type vs. IFN-!R-/- hearts. 
B, Comparable IL-17 production of heart-infiltrating T cells at days 21 and 30 in immunized 
IFN-!R-/- mice. 105/ml of infiltrating CD3+ cells were isolated from diseased hearts and re-
stimulated with anti-CD3/anti-CD28 for 24 hours. p = 0.21. 
 
In wild-type mice, numbers of heart-infiltrating CD11b+ monocytes peak 21 
days after immunization, and slowly resolve thereafter. In contrast, 
autoimmune myocarditis shows a progressive and severe disease course in 
IFN-!-/- or IFN-!R-/- mice (48, 49). Together with the in vitro findings described 
above, we hypothesized that the progressive disease course in IFN-! deficient 
mice reflects a defective, IFN-!-dependent, CD11b+ monocyte-mediated 
negative feedback loop.  
As illustrated in Fig. 5.7A, diseased IFN-!R-/- mice show similar patterns of 
cardiac infiltrations as wild-type mice with myocarditis, except the relative 
numbers of heart infiltrating T cells, which are consistently higher in IFN-!R-/- 
hearts. Furthermore, and in contrast to wild-type mice (Fig. 5.3A), IL-17 
production of heart-infiltrating T cells did not differ between days 21 and 30 in 
IFN-!R-/- mice (Fig. 5.7B). 
To specifically address the role of heart-infiltrating CD11b+ monocytes as key 
players in an IFN-!-dependent negative feedback loop in vivo, we took 
advantage of the IFN-! producing capacity of autoreactive T cells in 
immunized mice lacking the IFN-! receptor (47). Accordingly, we injected 
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groups of immunized IFN-!R-/- mice with either IFN-!R-/- or IFN-!R+/+ CD11b+ 
monocytes, and analyzed myocarditis severity. As illustrated in Fig. 5.8 A & B, 
IFN-!R-/- mice injected with IFN-!R-/- monocytes exhibited severe myocarditis 
at day 21, whereas myocarditis largely resolved in IFN-!R+/+ monocyte treated 
animals. In parallel, proliferation responses of in vitro MyHC-" re-stimulated 
CD4+ T cells were markedly reduced in animals treated with IFN-!R+/+ 
monocytes (Fig. 5.8C). Of note, IFN-!R+/+ monocytes were not effective in 
IFN-!-/- mice, confirming the idea that IFN-! directly acts on injected 
monocytes. These in vivo findings illustrate, that heart-infiltrating monocytes 
are the cellular key player in an IFN-!-signaling-dependent negative feedback 
loop in autoimmune heart disease. 
Figure 5.8. A, Reduced disease severity in IFN-!R-/- mice treated with IFN-!R+/+ CD11b+ 
monocytes. MyHC-"/CFA-immunized IFN-!R-/- mice were injected on days 7, 9, and 11, with 
either IFN-!R+/+ or IFN-!R-/- CD11b+ monocytes and sacrificed on day 21. X25 and X200 
original magnifications are shown.  
B, IFN-!R+/+ CD11b+ monocytes abrogate chronic myocarditis in IFN-!R-/- mice. Individual IFN-
!R-/- mice were treated with either IFN-!R-/- (") or IFN-!R+/+ (!) CD11b+ as indicated above. *p 
= 0.016.  
C, CD11b+ monocyte treatment suppresses proliferation of CD4+ T cells in IFN-!R-/- mice. 
CD4+ T cells were isolated from either IFN-!R-/- (") or IFN-!R+/+ (!) CD11b+ monocyte treated 
IFN-!R-/- mice and re-stimulated on irradiated MyHC-"-pulsed APC.  
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5.6  MyHC-"-specific Th1 T cells protect from Th17-induced myocarditis  
So far, we provided in vitro and in vivo evidence for an IFN-!-dependent 
negative feedback mechanism mediated by CD11b+ monocytes. 
Immunization of wild-type mice, however, results in the expansion of a mixed 
population of MyHC-"-specific CD4+ T cells. So far, it is not clear whether 
heart-specific CD4+ Th1 cells are part of this organ specific feedback loop, or 
whether they simply act as one out of several “bystanders” providing IFN-!. To 
address this question in vivo, we generated MyHC-"-specific CD4+ Th17 cell 
lines and co-injected 0.5 x 107 cells/mouse together with either 0.5 x 107 
activated MyHC-"-specific CD4+ Th1 cells or OVA-specific DO11.10 
transgenic CD4+ Th1 cells in groups of RAG2-/- mice lacking functional B and 
T cells. As illustrated in the table, we found that co-transfer of MyHC-"-
specific Th1 CD4+ T cells but not OVA-specific DO11.10-transgenic CD4+ Th1 
cells protected from myocarditis development after adoptive transfer of 
autoreactive, heart-specific CD4+ Th17 cells. These findings suggest that 
heart-specific CD4+ Th1 cell responses are a prerequisite for the initiation of 
an IFN-!-dependent and CD11b+ monocyte-mediated negative feedback 
mechanism confining heart-specific autoimmunity and myocarditis. 
Co-transfer of MyHC-"-specific CD4+ Th17 cell lines together with OVA-
specific vs. MyHC-"-specific CD4+ Th1 cell lines 
Th17 T cell lines 
[numbers/specificity] 
Th1 T cell lines 
[numbers/specificity] 
Disease prevalence 
day 12  
[# diseased/# treated] 
Severity grade 
[median -range ] 
0.5 x 107 / MyHC-" 0.5 x 107 / MyHC-" 2/6 0 (0-1)* 
0.5 x 107 / MyHC-" 0.5 x 107 / OVA
 
6/6 1.5 (1-3)* 
0.5 x 107 / MyHC-" none
 
5/5 2 (1-2) 
 
*p < 0.05 for the comparison of severity grades in Th17 injected mice co-
transferred with MyHC-"- vs. OVA-specific Th1 cells (Mann Whitney U). 
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5.7  CD8"+ DC treated with TNF-" or LPS-"CD40 have the same potential to 
stimulate T cells, but polarize different CD4+ T cell subsets  
After showing that CD4+ Th1 cells conferred protection from EAM, we 
wondered whether an early polarization of IFN-!-producing CD4+ Th1 cells 
negatively regulate CD4+ Th17 cell differentiation. For this purpose, we sought 
a specific subpopulation of APC that was able to especially differentiate CD4+ 
Th1 cells. We focused our efforts on splenic dendritic cells. In fact, among the 
five described splenic DC subpopulations (103), it has been reported that DC 
expressing CD8"+ are prone to induce IFN-!-producing CD4+ Th1 cells in vitro 
and in vivo (104, 107). We hypothesized that a vaccination strategy with 
activated splenic CD8"+ DC pulsed with heart-peptide could induce an early 
Figure 5.9. Surface marker phenotype and cytokine production of DC used to 
vaccinate mice. A, Characteristic surface markers of DC generated and sorted from FLT3L-
treated mice. The expression of CD8"+, CD11c, and CD11b was analyzed by FACS to check 
the purity of the sorted DC population.  
B, Expression of surface costimulatory markers MHCII, CD40, CD80, and CD86 on CD8"+ 
DC stimulated for 4 h with different adjuvants, analyzed by FACS. The histograms were gated 
on CD8"+/CD11c+ DC. The grey area represents the isotype control.  
C, CD8"+ DC sorted from FLT3L-treated mice were stimulated for 4 h with TNF-" or LPS-
"CD40. Supernatants were tested for IL-1#, IL-6, TGF-#, and IL-23 using commercially 
available ELISA kits.  
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polarization of IFN-!-producing CD4+ Th1 cells, which, in turn, would inhibit 
the proliferation of pathogenic and auto-aggressive IL-17-producing CD4+ 
Th17 cells. 
CD8"+ dendritic cells were sorted from FLT3L-treated spleens and then 
stimulated in vitro for 4 h with TNF-" or LPS plus "-CD40. Cell suspensions 
were immediately harvested and centrifuged to collect pure supernatants for 
cytokines measurement, while DC were analyzed by FACS for surface 
activation markers. As shown in Fig. 5.9A, splenic DC highly expressed CD8" 
and CD11c, but low CD11b, indicating that these DC belong to the lymphoid 
lineage. The surface marker phenotype of TNF/CD8"+ and LPS-
"CD40/CD8"+ displayed elevated levels of the costimulatory molecules CD40 
and CD80, while CD86 and MHC II expression was similar in unstimulated 
and stimulated cells (Fig. 5.9B). Sandwich ELISA with DC culture supernatant 
Figure 5.10. Potential of CD8"+ DC to stimulate and polarize CD4+ Th cells. A, CD8"+ 
DC were sorted from FLT3L-treated mice, pulsed with OVA323-339-peptides and untreated or 
stimulated with TNF-" or LPS/"CD40 for 4 h, washed, and finally resuspended with titrating 
amounts of CD4+ T cells sorted from OVA-transgenic DO11.10 mice. Co-cultures were 
incubated for 24 h (  ), 48 h (  ), and 72 h (  ). Proliferation of CD4+ T cells was assessed by 
3H-thymidine incorporation.  
B, OVA323-339-peptide-pulsed TNF/CD8"+ or LPS-"CD40/CD8"+ were intravenously injected 
into OVA-transgenic DO11.10 mice. Splenocytes were restimulated with OVA323-339-peptides 
for 24 h and with PMA/IO/BFA for the last 4 h to analyze intracellular cytokines production by 
FACS. The percentage of peptide-specific IFN-! and IL-17 production refers to CD4+/KJ1-26+ 
cells.    
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was performed to measure cytokines production after 4 hours incubation with 
TNF-" or LPS/"-CD40. The production of cytokines varied remarkably 
between the differentially stimulated DC. High levels of IL-1# and IL-6 were 
secreted by LPS-"CD40/CD8"+ compared to TNF/CD8"+, but high levels of 
TGF-# were measured by TNF/CD8"+ compared to LPS-"CD40/CD8"+ (Fig. 
5.9C). The differences in IL-23 production were not significant (p = 0.166). 
The profile of cytokines produced by LPS-"CD40/CD8"+ suggests a high 
potential to differentiate naïve CD4+ T cells in pathogenic CD4+ Th17 cells, 
which are the most auto-aggressive mediators in EAM induction. 
Dendritic cells are potent antigen presenting cells (83-85). They capture and 
process antigens displaying large amounts of MHC-peptide complexes at their 
surface, priming naïve T cells through the affinity between MHC-peptide 
complexes and TCR and the cooperation of other costimulatory molecules 
(83). To investigate the potential of CD8"+ DC to prime naïve T cells, we 
pulsed CD8"+ DC with OVA323-339-peptides in the presence or absence of 
TNF-" or LPS plus "-CD40 for 4 hours. DC were immediately washed to 
arrest the stimulation, and then resuspended in culture medium containing 
naïve DO11.10 transgenic CD4+ T cells. After 24, 48, and 72 hours, T cell 
proliferation was assessed by incorporation of 3H-thymidine. Of note, both 
TNF-" and LPS-"CD40 treatments did not affect the CD8"+ DC potential to 
prime and stimulate CD4+ T cells (Fig. 5.10A). Titrating amounts of untreated 
CD8"+ DC, as well as TNF/CD8"+ and LPS-"CD40/CD8"+ were equally able 
to induce proliferation after different incubation times. To verify which CD4+ Th 
cell subpopulations were primed by OVA323-339-pulsed TNF/CD8"+ or LPS-
"CD40/CD8"+, we injected CD8"+ DC intravenously into DO11.10 transgenic 
mice. After two days, splenocytes were collected from treated mice and 
restimulated with PMA, ionomycin, and Brefeldin A, to assess the intracellular 
cytokines production. Both CD8"+ DC stimulations induced an elevated 
antigen-specific production of IFN-!, which suggested a predominant CD4+ 
Th1 cell development (Fig. 5.10B). On the contrary, only LPS-"CD40/CD8"+ 
induced a relevant antigen-specific production of IL-17 compared to TNF-"-
stimulated CD8"+, which did not produce any IL-17 at all (Fig. 5.10B). These 
data indicate that TNF/CD8"+ support the differentiation of IFN-!-producing 
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Figure 5.11. Vaccination with TNF-"-stimulated CD8"+ DC prevents EAM. A, Wild-type 
BALB/c mice were vaccinated 3 times at days -7, -5, -3, with 106 MyHC-"-loaded 
TNF/CD8a"+ or LPS-"CD40/CD8"+ each time. Vaccinated mice were immunized with 150 µg 
of MyHC-"/CFA at day 0 and day 7, and sacrificed at day 21. Histological severity scores of 
individual mice are shown. p = 0.0026 for TNF-"- vs. sham-treatment, p = 0.046 for LPS-
"CD40- vs. sham-treatment.  
B, Hematoxylin/eosin-stained sections, 25X and 200X of the original magnification are shown. 
C, Histological severity scores after vaccination (day 0), and after both vaccination and 
immunization (day 2, day 9, day 14, and day 21). Median of at least 3 mice and SD values are 
shown. 
 
CD4+ Th1 cells, which are favorable to protect from EAM, while LPS-
"CD40/CD8"+ support the polarization of both CD4+ Th1 and pathogenic IL-
17-producing CD4+ Th17 cells, which are auto-aggressive and favorable to 
induce EAM.  
 
5.8  Pre-vaccination with TNF-"-stimulated CD8"+ DC prevents EAM 
To analyze the potential of differentially stimulated CD8"+ DC to modulate 
EAM, TNF/CD8"+ or LPS-"CD40/CD8"+ were pulsed with MyHC-"-peptide 
for 4 h. Mice were pre-vaccinated three times, at days -7, -5, and -3. At day 0, 
we then immunized the pre-vaccinated animals with MyHC-"-peptides 
emulsified in CFA. The same mice were boosted at day 7. Sham-treated 
control mice were pre-vaccinated with PBS only and immunized at day 0 and 
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day 7 with MyHC-"-peptides emulsified in CFA. Twenty-one days after the 
first immunization, the hearts were removed and examined for heart-infiltrating 
cells. As expected, immunized sham-vaccinated control mice exhibited severe 
myocarditis at day 21, while mice that received LPS-"CD40/CD8"+ had only a 
slight decrease of EAM incidence (Fig. 5.11 A and B) that, however, was 
statistically significant (p = 0.046). In contrast, vaccination with TNF/CD8"+ 
led to a relevant prevention of the disease (p = 0.0026) (Fig. 5.11 A and B). 
To exclude that the vaccination altered the course of the disease, preceding 
the onset of myocarditis earlier than 21 days after the first immunization, we 
sacrificed vaccinated and vaccinated/immunized mice at different time points. 
We examined hearts for infiltrating cells at day 0, day 2, day 9, day 14, and, 
as mentioned before, at day 21. Examination of mice at day 0 allowed us to 
verify that the vaccination did not cause any side effect such heart 
inflammation or EAM. In fact, MyHC-"/CFA-immunized mice vaccinated with 
TNF/CD8"+ always showed very low or irrelevant heart score disease values 
(Fig. 5.11C), suggesting that this vaccination method, in addition to prevent 
EAM, was not pathogenic and did not cause EAM. Vaccination with LPS-
"CD40/CD8"+ showed increased levels of EAM compared to TNF/CD8"+ at 
day 0, comparable levels after MyHC-"/CFA immunization from day 2 until 
day 9, but again constantly increased levels of heart-infiltrating cells from day 
9 to day 21 (Fig. 5.11C). This suggested that LPS-"CD40/CD8"+ vaccination 
was not optimal to prevent and protect mice from EAM. Sham-vaccinated 
control mice immunized with MyHC-"/CFA displayed the usual development 
of inflammatory heart-infiltrating cells characteristic for EAM. Taken together, 
these data indicate that vaccination with serial injections of TNF-"-stimulated 
CD8"+ DC pulsed with MyHC-"-peptides can protect from EAM. 
 
5.9  Antigen-specific IFN!-producing CD4+ Th1 confer protection from EAM  
To assess whether the mechanism of EAM prevention in mice vaccinated with 
TNF-"-stimulated CD8"+ DC was dependent on antigen-specific T cells, we 
adoptively transferred DO11.10 transgenic CD45.2 CD4+ T cells into CD45.1 
wild-type mice. One day later, TNF/CD8"+ or LPS-"CD40/CD8"+-sorted from 
CD45.2 mice were injected into the same CD45.1 recipient mice. Two days 
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Figure 5.12. TNF/CD8"+ prevent EAM supporting antigen-specific IFN-!-producing 
CD4+ Th1 cells. A, 106 CD4+ T cells sorted from OVA transgenic DO11.10 mice were 
intravenously injected into each CD45.1 wild-type mouse. One day later, 105 OVA323-339-pulsed 
CD8"+ DC stimulated with TNF-" or LPS-"CD40 were intravenously injected into the same 
CD45.1 recipient mice. After two days, spleens were extracted and splenocytes were 
restimulated with PMA/IO/BFA for 4 h. FACS staining for intracellular IFN-! measurement is 
shown for both CD4+CD45.1 and CD4+CD45.2+ cells.  
B, Mice vaccinated and immunized as described in Fig. 6.3 were sacrificed at day 2 and day 
9. After 48h restimulation with 2 µg/ml MyHC-"-peptides, CD4+ Th cells were intracellularly 
analyzed for IFN-! production by FACS. 
 
after CD8"+ DC injection, spleens were removed and cell suspensions were 
analyzed for intracellular cytokine production. As shown in Fig. 5.12A, 
restimulated CD4+ T cells from CD45.1 recipient mice produced low levels of 
IFN-! after injection of TNF/CD8"+ or LPS-"CD40/CD8"+, suggesting that 
CD8"+ DC did not induce peptide-unspecific T cells responses. In contrast, 
adoptively transferred DO11.10 transgenic CD45.2 CD4+ T cells released high 
amounts of IFN-!, indicating that CD8"+ DC triggered antigen-specific CD4+ 
Th1 cells to produce IFN-! (Fig. 5.12A). As mentioned before, CD4+ T cells 
from mice vaccinated with peptide-loaded CD8"+ DC showed an increased 
antigen-specific production of IFN-!. To understand whether the self-peptide-
specific CD4+ Th1 cell response was restricted to the vaccination period, mice 
vaccinated with MyHC-"-pulsed CD8"+ DC and then immunized with MyHC-
"/CFA were examined 2 days and 9 days after the first immunization. 
Splenocytes suspensions were restimulated with MyHC-"-peptide for 48 
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hours for intracellular cytokine analysis. As expected, IFN-! was highly 
produced by CD4+ Th1 cells primed by TNF/CD8"+ at day 2 and day 9, 
reflecting the protective role of IFN-! in EAM (Fig. 5.12B). On the contrary, the 
vaccination effect of LPS-"CD40/CD8"+ was already reduced 2 days after the 
first immunization, as demonstrated by low IFN-! production compared to 
CD4+ Th1 cells from TNF/CD8"+ vaccinated mice (Fig. 5.12B). These data 
indicate that vaccination with TNF/CD8"+ supports and induces CD4+ Th1 
polarization, allowing the suppression of pathogenic and auto-aggressive IL-
17-producing CD4+ Th17 cells. In addition, the success of this vaccination 
strategy emphasizes the protective role of IFN-!-producing CD4+ Th1 cells in 
EAM. 
 
5.10  GITR+ Treg play no role in TNF-"-DC-mediated protection from EAM 
Several CD4+ T cell subpopulations produce IFN-!. Given the efficacy of the 
DC vaccination strategy, the question arises whether protection is indeed 
conferred by self-antigen-specific CD4+ Th1 cells, or whether the pre-
vaccination strategy also acts on regulatory T cells. For this reason, we 
specifically addressed the role of regulatory T cells (Treg) in our vaccination 
strategy. To this end, we analyzed the number of CD4+FoxP3+GITR+ Treg 
and their potential to produce IFN-! in the spleen of vaccinated mice (day 0). 
Surface marker analysis revealed that both TNF/CD8"+- or LPS-
"CD40/CD8"+-vaccinated mice did not display relevant differences compared 
to sham-vaccinated control mice among the CD4+FoxP3+GITR+ Treg 
population (Fig. 5.13A). Importantly, levels of IFN-! expressed by Treg were 
very low and comparable in both CD8"+ DC-vaccinated mice and sham-
vaccinated control mice (Fig. 5.13A).  
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As CD4+FoxP3+GITR+ Treg are known to modulate and protect from EAM 
(115), we investigated whether CD8"+ DC vaccination altered the inhibitory 
potential of Treg. For this purpose, we isolated splenocytes from a mouse with 
myocarditis and co-cultivated them with titrating amounts of GITR+ Treg 
sorted from CD8"+ DC-vaccinated or sham-vaccinated mice at day 0. As 
shown in Fig. 5.13B, all GITR+ Treg were equally efficient in inhibiting 
proliferating MyHC-"-specific splenocytes. Thus, we did not observe any 
functional difference between Treg sorted from TNF/CD8"+-, LPS-
"CD40/CD8"+-, or sham-vaccinated mice. These findings suggest that the 
immunomodulatory potential of Treg was not affected by our pre-vaccination 
strategy. Accordingly, CD4+FoxP3+GITR+ Treg are not involved in the 
protective mechanism induced by CD8"+ DC vaccination.  
Figure 5.13. CD4+FoxP3+GITR+ Treg did not show any difference in number and 
inhibitory potential. A, Mice vaccinated at days -7, -5, and -3, with TNF/CD8"+ or LPS-
"CD40/CD8"+ were sacrificed at day 0. Splenocytes were stained for surface markers with 
CD4, GITR, and for intracellular markers with FoxP3. For intracellular IFN-! detection by 
FACS, spleen cell suspensions were restimulated for 4 h with PMA/IO/BFA. B, 105 
splenocytes from a mouse with myocarditis were co-cultivated for 48 h with titrating amount of 
GITR+ Treg (104, 103, 102) sorted from differently vaccinated mice (day 0) in the presence of 2 




6  Discussion 
 
In the first part of my thesis, I provided evidence for a dual role of CD11b+ 
monocytes, the major heart-infiltrating cells during the disease course of EAM. 
In the short term, CD11b+ monocytes represent the major cellular substrate of 
IL-17-induced acute inflammation. In the long term, however, CD11b+ 
monocytes mediate a disease limiting IFN-!-triggered negative feedback loop, 
which suppresses heart-specific T cell responses.  
In the second part of my thesis, I developed the basics for a novel vaccination 
strategy to prevent EAM. In addition, I provided for the first time in vivo 
evidence that an established Th1 memory might prevent Th17-mediated 
autoimmunity in vivo. Pretreatment with serial injections of self-peptide-pulsed 
and TNF-"-stimulated splenic CD8"+ DC triggered a Th1 biased MyHC-"-
specific CD4+ T cell response and protected mice from EAM by suppressing 
CD4+ Th17 cell lineage expansion.  
 
6.1  The dual role of CD11b+ monocyte-like cells in EAM 
In the EAM model, the extent of the cardiac infiltrates peaks around day 21 
after the first immunization. According to our data, IL-17 released by 
autoreactive CD4+ Th17 cells directly promotes the recruitment of bone 
marrow-derived CD11b+ monocytes to the heart. CD11b+ monocytes 
represent the major population of heart-infiltrating cells. Later on, during the 
disease course, mononuclear infiltrates and intra-cardiac IL-17 release 
spontaneously resolve in wild-type mice. This, however, is not the case in 
IFN-!R-/- or IFN-!-/- mice, which show ongoing severe inflammation and a 
persistent autoreactive T cell response. Our data indicate that heart-infiltrating 
CD11b+ monocytes are key players in a negative feedback loop suppressing 
autoreactive heart-specific T cells. This negative feedback loop is IFN-!-
dependent and nitric oxide-mediated. In fact, IFN-! signaling is required on 
CD11b+ monocytes but not on T cells, because IFN!-R+/+ CD11b+ monocytes 
were sufficient to abrogate EAM in IFN-!R-/- mice.  
So far, EAM has been recognized as an autoimmune disease developing 
independently of Th1/Th2 polarization (47). It has been shown recently that 
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IL-6, which is essential for the induction of Th17 T cells (46), and IL-23-
promoting Th17 expansion, are both critical for EAM development (47, 57). In 
extension of these findings, our data prove the direct pathogenic role of IL-17 
in EAM development, because IL-17 depletion prevents EAM development. 
Furthermore, we show that IL-17 is responsible for the recruitment of myeloid-
derived monocytes representing the major heart infiltrating cells in EAM. 
Although the exact mechanism could be speculative, it might include direct 
chemotactic effects, as suggested in vitro for pulmonary macrophages (116). 
Indeed, we found markedly suppressed MCP-1 and MIP-1" mRNA levels in 
hearts of anti-IL-17-treated immunized mice compared to controls. 
Furthermore, mice lacking the CCR2 receptor for MCP-1 and the CCR5 
receptor for MIP-1", respectively, had been reported to be resistant to EAM 
(114). In addition, we found reduced mRNA expression of the chemotactic 
ligand SDF-1 acting through the CXCR4 receptor on injected monocytes. 
Nevertheless, we cannot exclude that other IL-17-dependent mediators or 
receptors might also be involved in the recruitment of inflammatory cells. IL-17 
could also act on stromal endothelial cells in inflamed tissue to induce the 
secretion of neutrophil-attracting factors such as IL-8, CXCL1 or GM-CSF 
(117-119).  
Phenotypically, the CD11b+ heart-infiltrating cells represent a heterogeneous 
population of largely immature CD45, CD14, F4/80 and CXCR4 positive 
monocytes expressing low levels of MHC class II and Gr-1. Culturing bone 
marrow in the presence of M-CSF yields a population of cells with largely 
identical surface marker expression pattern. Interestingly, recent data 
demonstrated that polymicrobial sepsis results in the expansion of an 
immature Gr-1+CD11b+ cell population with T cell suppressing properties 
(120). In contrast to our observations in the EAM model, these cells were Gr-
1+ and most expressed CD31, a marker of immature myeloid cells. Obviously, 
the severe systemic inflammatory response associated with sepsis results in 
the mobilization of a more immature myeloid lineage committed cell 
population from bone marrow. Nevertheless, the heart-infiltrating CD11b+ cells 
still show some maturation capacity, because they up-regulate NOS2 and 
MHC class II in the presence of combined IFN-! exposure and TLR4 
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stimulation (see Fig. 5.6). This final maturation step appears critical for the 
induction of the above mentioned negative feedback loop.  
Mice lacking T-bet-/-, a T-box transcription factor required for Th1 cell 
differentiation and IFN-! production, show a heart-localized up-regulation of 
IL-17 production and higher disease scores (47). In the same report, it was 
demonstrated that the IL-23 subunit IL-12p40, but not the IL-12p70 specific 
subunit IL-12p35, are critical for myocarditis development. The idea that IL-23 
is critical for Th17 T cell expansion and EAM development fits to the 
observation that STAT4-/- and STAT4-/-IFN-!-/- mice, but not IFN-!-/- mice, are 
protected from EAM (50). In fact, STAT4 signaling is required for IL-17 
production in response to IL-23 (54). Furthermore, our findings fit earlier 
observations of enhanced myocarditis susceptibility in IFN-!-/- and IFN-!R-/- 
mice (48-50). Indeed, we found markedly increased IL-17 levels after in vitro 
re-stimulation of heart infiltrating T cells from IFN-!-/- and IFN-!R-/- mice (Fig. 
5.7B). Whereas the capacity of heart infiltrating T cells to release IL-17 
successively decreases in wild-type mice after day 21, IL-17 release and 
infiltrations with mononuclear inflammatory cells persist in the hearts of IFN-!-/- 
and IFN-!R-/- mice up to two months after immunization. Anti-IL-17 treatment 
reduced monocyte infiltrations and myocarditis scores in IFN-!-/- mice, 
underscoring the relevance of persistent intra-cardiac IL-17 release for the 
persistence of cardiac inflammation in the absence of IFN-!. Together with the 
enhanced disease scores of IFN-!-/- mice (48, 50) and the increased intra-
cardiac IL-17 levels, the latter observations suggest a direct anti-inflammatory 
role for IFN-! in Th17-mediated autoimmune myocarditis in vivo and fit the 
perception that IFN-! negatively regulates Th17 T cell expansion (53, 121). 
Importantly, my data argue against an IFN-!-dependent role for regulatory T 
cells in EAM suppression (122-124), because wild-type monocytes alone 
were sufficient to suppress disease in IFN-!R-/- mice lacking IFN-! signaling 
on T cells. Mechanistically, the in vitro data rather suggest that upon IFN-! 
exposure, monocytes take a final maturation step and mediate T cell 
suppressive effects by release of nitric oxide (Fig 6.1). Another IFN-!-
dependent mechanism might include the induction of indoleamine-2,3-
dioxygenase (IDO) on antigen-presenting cells (125). However, differences in 
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Figure 6.1. The negative feedback mechanism which confines EAM. Cardiac damage 
results in release of heart-specific self-antigens. In the presence of non-specific adjuvants, 
APC-internalizing cardiac self-antigens get activated beyond a threshold level and promote 
heart-specific autoimmunity. Pro-inflammatory cytokines, such as IL-1, IL-6, and TGF-#, 
support the differentiation of auto-aggressive CD4+ Th17 cell, while IL-23 is necessary for 
survival and expansion of the CD4+ Th17 lineage. Heart-specific CD4+ Th17 cells infiltrate into 
the heart inducing inflammatory signals. IL-17 and other macrophage-attracting chemokines 
support the recruitment of inflammatory cells into the heart. IFN-! stimulates heart-infiltrating 
monocytes/macrophages to produce nitric oxide. Nitric oxide reversibly inhibits T cell 
proliferation, resolving the disease.  
 
systemic serum levels of IDO metabolites between IFN-!+/+ and IFN-!-/- mice 
were never found. According to our data, the IFN-!-triggered NOS2 
upregulation and nitric oxide release is synergistically enhanced by the 
stimulation of Toll like receptor 4, but not by TNF-" (Fig. 5.6). 
The role of nitric oxide in immune-mediated diseases is still controversial 
(126, 127). Nitric oxide has been shown to act as a potent cytotoxic effector 
molecule in immune defence and to induce tissue damage in autoimmune 
diseases (128, 129). In fact, increased levels of human NOS2 mRNA have 
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been measured in the brain of multiple sclerosis patients and have been 
correlated to chronic active demyelinating lesions (130), while EAE in 
susceptible mice was reduced by administration of a NO-inhibitor (131). On 
the other hand, many studies reported that NO exerts anti-inflammatory 
effects. In fact, nitric oxide represents a short living mediator of reversible T 
cell growth arrest. Importantly, physiological levels of nitric oxide inhibit T cell 
proliferation in vitro reversibly, without induction of apoptosis or affecting the 
capacity of the cells to produce cytokines (80, 132, 133). In fact, several lines 
of evidence suggest that NO-dependent feedback mechanisms confining T 
cell expansion might play an important modulatory role in various diseases. In 
autoimmune disease models, for example, NO limits autoreactive T cell 
expansion in myocarditis (134), myasthenia gravis (135), experimental allergic 
encephalomyelitis (136), and in a mouse model of pulmonary graft versus 
host-disease (137). In the context of atopic asthma, IFN-!-releasing Th1 cells 
function in concert with human bronchial epithelial cells, which serve as a 
major source of NO to inhibit T cell proliferation at the potential lesional sites 
in asthma. In vitro, the NO-induced T cell growth arrest was reversible and 
STAT5-dependent (133).  
In the EAM model, MyHC-"/CFA immunization results in the generation of 
heart-specific Th17 as well as Th1 T cells. In wild-type mice, however, heart-
infiltrating CD8+ T cells, but not the CD3+CD8- T cells, represent the major 
source of IFN-! within the inflamed myocardium at day 21 after immunization 
(47). Nevertheless, co-injection of MyHC-" specific Th1 T cells prevented 
disease development in RAG2-/- mice 12 days after adoptive transfer of 
MyHC-" specific Th17 T cells. These findings indicate a negative regulatory 
role for Th1 T cells in autoimmune myocarditis. Given the fact that heart-
infiltrating CD4+ T cells do not release IFN-! at day 21, Th1 cells must either 
exert their inhibitory effects early during disease development or outside the 
heart. Nevertheless, IFN-! released from heart-infiltrating CD8+ T cells or NK 
cells might still activate heart-infiltrating CD11b+ monocytes triggering local 
nitric oxide release and suppression of activated, heart-infiltrating Th17 cells. 
This negative feedback mechanism allows the immune system to promote the 
quick IL-17-dependent recruitment of monocytes to a potentially infected site. 
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IFN-!, on the other hand, is required for the optimal activation of monocytes 
and macrophages dealing with an infective agent. At the same time, IFN-! 
limits the expansion of activated T cells and protects from exaggerated or 
even auto-aggressive T cell responses. This negative feedback mechanism 
might regulate the expansion of CD4+ Th17 cells in the peripheral lymphatic 
organs. In fact, a biased expansion of heart-specific IFN-!-producing CD4+ 
Th1 cells would negatively act on the polarization and expansion of 
pathogenic CD4+ Th17 cells. This could completely prevent the development 
of heart-specific CD4+ Th17 cells in the periphery, protecting from EAM.    
Our data suggest that the view on the role of heart-infiltrating monocytes in 
autoimmune heart disease needs to be revised. So far, histological evaluation 
of cardiac infiltrates represented the diagnostic gold standard. Accordingly, 
severity grading of myocarditis strongly depends on the extent of 
mononuclear infiltrates, including monocytes and macrophages (26, 138). Our 
experiments suggest that these heart-infiltrating monocytes also reflect the 
first step of a negative feedback loop suppressing heart-specific T cells and 
initiating the healing process. This idea nicely fits the observation of a 
favorable disease prognosis of patients with fulminant myocarditis 
characterized by massive infiltrations of mononuclear cells (139). Regarding 
histology as readout for the disease progression into chronic myocarditis, we 
postulate that not the extent of infiltrates per se but rather the presence of IL-
17-producing autoreactive CD4+ Th17 cells would correlate with potential 
adverse outcome. 
In conclusion, we provide for the first time evidence for a protective role of 
bone marrow-derived CD11b+ monocytes in autoimmune myocarditis. In fact, 
heart-infiltrating monocytes represent a key element in an IFN-!-dependent 
negative feedback loop limiting cardiac inflammation. 
  
6.2  A CD8"+ DC-based vaccination strategy against EAM 
Serial intravenous injections of MyHC-"-pulsed and TNF-"-stimulated CD8"+ 
dendritic cells (TNF/CD8"+) were used to develop a vaccination strategy to 
prevent EAM. In fact, providing evidence that a heart-specific CD4+ Th1-
induced IFN-! response supported protection from EAM, we hypothesized 
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that a vaccination strategy to mediate the polarization of IFN-!-producing 
CD4+ Th1 cells in the peripheral lymphnodes negatively regulated the 
expansion of autoreactive CD4+ Th17 cells. For the differentiation of CD4+ 
Th1 cells, we used splenic CD8"+ DC, which have been described to prime 
IFN-!-producing T cells. Other DC subsets were not helpful for this purpose. 
Indeed, splenic CD8"- DC polarized IL-4-producing T cells, while bmDC 
cultured in GM-CSF induced a CD4+ Th17-biased response.     
We showed a tolerogenic potential of TNF/CD8"+, which can be explained by 
the low proinflammatory cytokine secretion upon stimulation. In fact, 
TNF/CD8"+ produced low levels of IL-1# and IL-6, and not significant 
increased levels of IL-23, when compared to LPS-"CD40/CD8"+. 
Phenotypically, unlike the untreated CD8"+ DC, TNF/CD8"+ expressed higher 
levels of the costimulatory surface molecules CD40, and CD80. However, 
TNF/CD8"+ and LPS-"CD40/CD8"+ essentially did not differ in their 
expression of costimulatory molecules and their priming capacity for naïve T 
cells. They differed, however, in their potential to polarize the CD4+ Th 
response. In fact, TNF/CD8"+ supported the differentiation of IFN-!-producing 
CD4+ Th1, while LPS-"CD40/CD8"+ supported both, IFN-!-producing CD4+ 
Th1 and IL-17-producing CD4+ Th17. These findings are in line with in vitro 
and in vivo data, suggesting that CD8"+ DC promote peripheral tolerance 
(140) and polarize IFN-!-producing CD4+ Th1 cells (104-106, 141). We 
demonstrated, as well, the ability of TNF/CD8"+ to promote a CD4+ Th1 cell-
biased response, but the potential of LPS-"CD40/CD8"+ to promote both 
CD4+ Th17 and Th1 cells was not yet described. This observation can be 
explained by TLR stimulation, increasing the production of various 
inflammatory cytokines (142). This was described in an autoimmune arthritis 
mouse model with mice lacking TLR4, which were protected against severe 
disease, demonstrating that TLR4 modulates the CD4+ Th17 cell population 
and IL-17 production (142). Studies in EAM reported, as well, that TLR4 
activation supports the development of CD4+ Th17 cells (58). Taken together, 
CD4+ Th1 polarization is a prerogative of TNF-"/CD8"+, while differentiation 
of CD4+ Th17 is supported by the TLR-activated CD8"+ DC cells.  
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Compared to LPS-"CD40/CD8"+-treated mice, TNF/CD8"+-pretreated mice 
mount a Th1 response and are protected from subsequent MyHC-"/CFA 
immunization. Indeed, two and nine days after the first immunization, MyHC-
"-specific IFN-! production showed similar levels in LPS-"CD40/CD8"+-
vaccinated mice and sham-prevaccinated mice. In contrast, Elevated IFN-! 
levels were increased in TNF/CD8"+-prevaccinated mice at the same time 
points. Thus, it is then conceivable that the in vivo expansion of antigen-
specific CD4+ Th1 cells, i.e. generation of a Th1 memory, allows a rapid 
response of primed IFN-!-producing T cells at the draining lymphnodes after 
MyHC-"/CFA immunization. This rapid CD4+ Th1 response 
abrogates/suppresses the pathogenic CD4+ Th17 responses immediately. 
This mechanism has already been shown and demonstrated in vitro (51, 53, 
143, 144). In fact, neutralization of IFN-! in vitro increased the number of IL-
17-producing Th17 cells. The number of CD4+ Th17 cells was then further 
increased by the addition of IL-4-neutralizing antibodies, indicating that both 
IFN-! and IL-4 can inhibit the expansion of CD4+ Th17 cells in vitro (51, 53). 
We, on the other hand, provide for the firs time in vivo evidence that CD4+ 
Th1 responses negatively regulate CD4+ Th17-mediated autoimmunity. 
The factors regulating CD4+ Th1 cell differentiation are essential for the 
expansion, the stability, and the survival of the lineage. The expansion of 
effector and memory Th1 cells is defined by several factors, like the duration 
of antigenic stimulation (145), the type of antigen presenting dendritic cells, 
and the cytokine milieu (146). In fact, the duration of antigen stimulation 
determines whether naïve or effector Th cell will be activated or deleted. 
Under prolonged stimulation, for instance, effector Th cells present a 
decreased capacity to proliferate and die earlier (145). Thus, it was not 
surprising that vaccination with high amounts of peptide-pulsed and 
stimulated CD8"+ DC did not protect from EAM after induction of the disease. 
This can be explained by a too strong induction of CD4+ Th1 cells by CD8"+ 
DC, which led effector and memory CD4+ Th1 cells to death after the second 
and the third injection. Moreover, we used MyHC-"-loaded and TNF-"-
stimulated or LPS-"CD40-stimulated bmDC (see “Material and methods”) as 
control, to evaluate the differences between bmDC and CD8"+ DC. The 
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potential of bmDC to induce proliferation of naïve CD4+ T cells in vitro was 
considerably increased compared with CD8"+ DC. Furthermore, we already 
knew that bmDC were high pathogenic and induced strong autoimmune 
myocarditis between 10 and 14 days after the first injection (44-46). As 
expected, mice vaccinated three times with bmDC (stimulated with TNF-" or 
with LPS-"CD40) showed severe myocarditis with huge amounts of heart-
infiltrating cells at day 10, while vaccination with CD8"+ DC was not 
pathogenic and induced only irrelevant myocarditis. On the level of the CD4+ 
Th cells, bmDC-pre-vaccinated diseased mice displayed high antigen-specific 
proliferation and IL-17 production, while CD8"+ DC-prevaccinated mice 
showed no relevant antigen-specific proliferation and no IL-17 production. In 
summary, TNF/CD8"+ DC were tolerogenic by promoting a non-pathogenic, 
protective peptide-specific IFN-!-producing CD4+ Th1 cell response, while 
bmDC were immunogenic, supporting peptide-specific IL-17-producing CD4+ 
Th17 cells. 
The cytokine milieu is very important for the polarization of CD4+ Th1 and 
Th17 cell lines. IL-12 has been and is still considered the most important 
cytokine to differentiate CD4+ Th1 cells (146-148). However, as mentioned in 
the “Introduction”, IL-12 is a heterodimer composed of two subunits, the p40 
and the p35. The p40 subunit is shared with IL-23, which is composed of the 
p40 and the p19 subunits. It has been shown that IL-23 is necessary for the 
survival and the expansion of the CD4+ Th17 lineage. For this reason, we did 
not take in consideration a measurement of IL-12 in the supernatants of 
stimulated CD8"+ DC, as IL-12p40 can support both CD4+ Th1 and Th17 
lineages (149). Other crucial cytokines involved in the polarization of the CD4+ 
Th17 lineage were detected in LPS-"CD40/CD8"+ supernatants and reflected 
the cytokine pattern necessary for CD4+ Th17 polarization (51-53). In fact, 
LPS-"CD40/CD8"+ were able to support the in vivo expansion of CD4+ Th17 
cells, while the development of CD4+ Th1 cells was supported by both 
TNF/CD8"+ and LPS-"CD40/CD8"+.  
IFN-! is produced by several cells. Besides T cells, also DC, NK cells, and 
Treg produce relevant amounts of IFN-! (123, 150-153). For this reason, we 
attempted to measure the production of IFN-! in the supernatants of 
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stimulated CD8"+ DC. In general, we observed that IFN-! production was not 
high, and comparing differentially stimulated CD8"+ DC with unstimulated 
CD8"+ DC, only LPS-"CD40/CD8"+ cells produced increased levels of IFN-!. 
However, this was not sufficient to explain any CD4+ Th1 or Th17 
differentiation potential by CD8"+ DC. Afterwards, we investigated the role of 
GITR+ Treg to produce IFN-! and to protect vaccinated mice from EAM. In 
fact, as Treg, under particular stimulatory signals, produce IFN-!, creating a 
regulatory mechanism to inhibit Th cells (123), we sought for a possible 
involvement of Treg in the protecting mechanism following vaccination. We 
decided to sort GITR+ Treg cells because they have been described as the 
only CD4+ T cell population expressing the typical Treg transcription factor 
FoxP3, which protect mice from EAM (115). GITR+ Treg sorted from 
vaccinated mice (day 0) did not present increased amounts of IFN-!, 
suggesting that Treg were not a determinant source of IFN-!.  
The last cell population we analyzed for IFN-! production was the natural killer 
population. NK cells belong to the innate immune system and act 
unspecifically in the early phase of inflammatory processes. The role of NK 
cells is still under investigation, but first results suggest that splenic NK cells 
from LPS-"CD40/CD8"+-treated mice present a reduced production of IFN-! 
compared to TNF/CD8"+ or sham-treated mice. However, it appears that this 
difference is not big enough to be considered significant. All together, the non-
relevant production of IFN-! by CD8"+ DC, Treg, and NK cells, supports our 
hypothesis that CD4+ Th1 cells are the crucial IFN-!-producing cells 
responsible for EAM protection.   
 
Taken together, my thesis provides a broader insight in the specific role of 
IFN-!- and IL-17-producing CD4+ T cells in inflammatory heart disease. I 
found that IFN-! can act as a negative regulator of CD4+ Th17-mediated 
inflammatory heart disease. Mechanistically, IFN-! inhibited the proliferation of 
autoreactive CD4+ Th17 cells promoting nitric oxide from heart-infiltrating 
CD11b+ monocytes. Nitric oxide, on the other hand, induced reversible growth 
arrest in activated CD4+ Th cells. Based on these findings, I used TNF-"-
activated, self-antigen-loaded splenic CD8"+ DC to selectively promote the 
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development of a heart-specific CD4+ Th1 memory response. Enhancing the 
heart-specific CD4+ Th1 response suppressed pathogenic CD4+ Th17 
responses and autoimmune myocarditis development after subsequent 
immunization. Our idea about the complementary role of IFN-! and IL-17 in 
inflammatory heart diseases represents a first step towards a novel 





7  List of abbreviations 
 
APC Antigen-presenting cells 
BALB/c Mouse strain (IAd haplotype) 
BFA Brefeldin A 
bmDC Bone marrow-derived dendritic cells 
BSA Bovine serum albumin 
CD Cluster of differentiation 
cDNA complementary DNA 
CFA Complete Freund’s adjuvant 
CFSE 5(6)-Carboxyfluorescein diacetate N-succinimidyl ester 
cpm Counts per minute 
CTLA Cytotoxic T lymphocyte antigen 
CVB3 Coxackievirus B3 
DC Dendritic cells 
DCM Dilated cardiomyopathy 
EAE Experimental autoimmune encephalomyelitis 
EAM Experimental autoimmune myocarditis 
ELISA Enzyme-linked immunosorbent assay 
FACS Fluorescence-activated cell-sorting 
FBS Fetal bovine serum 
FLT3 Fms-like tyrosine kinase 3 
FoxP3 Forkhead box P3   
GITR Glucocorticoid-induced TNFR family-related protein 
GM-CSF Granulocyte-macrophage colony stimulating factor 
H&E Hematoxilin & eosin 










LN Lymph node 
LPS Lipopolysaccharide 
MACS Magnetic affinity cell sorting 
MCP Monocyte chemoattractant protein 
M-CSF Macrophage colony stimulating factor 
MHC Major histocompatibility complex 
MIP Macrophage inflammatory protein 
MyHC-" Myosin heavy-chain-alpha 
NK Natural killer 
NO Nitric oxide 
NOS Nitric oxide synthase 
n.s. Not significant 
OVA323-339 Ovalbumin 323-339 peptide 
PAMPs Pathogen-associated molecular patterns 
PBS Phosphate buffered saline 
PMA Phorbol myristate acetate 
RAG Recombination activating gene 
RT-PCR Reverse transcriptase polymerase chain reaction 
s.c. Subcutaneous 
SD Standard deviation 
SDF-1 Stromal derived factor 1 
STAT Signal transducers and activators of transcription 
TCR T cell receptor 
TGF-# Transforming growth factor beta 
Th T helper cells 
TLR Toll-like receptors 
mTECs Medullary thymic epithelial cells 
TNF-" Tumor necrosis factor alpha 
Treg Regulatory T cells 
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